{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:31:52Z","timestamp":1791192712417,"version":"4.1.0"},"publisher-location":"Berlin, Heidelberg","reference-count":335,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642145407","type":"print"},{"value":"9783642145414","type":"electronic"}],"license":[{"start":{"date-parts":[[2010,10,26]],"date-time":"2010-10-26T00:00:00Z","timestamp":1288051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2010,10,26]],"date-time":"2010-10-26T00:00:00Z","timestamp":1288051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011]]},"DOI":"10.1007\/978-3-642-14541-4_9","type":"book-chapter","created":{"date-parts":[[2010,11,23]],"date-time":"2010-11-23T00:22:57Z","timestamp":1290471777000},"page":"325-371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["In Vitro and In Vivo Evidence for the Importance of Breast Cancer Resistance Protein Transporters (BCRP\/MXR\/ABCP\/ABCG2)"],"prefix":"10.1007","author":[{"given":"Henriette E. Meyer zu","family":"Schwabedissen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heyo K.","family":"Kroemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,10,26]]},"reference":[{"key":"9_CR1_9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1365-2125.2008.03184.x","volume":"66","author":"KK Adkison","year":"2008","unstructured":"Adkison KK, Vaidya SS, Lee DY, Koo SH, Li L, Mehta AA, Gross AS, Polli JW, Lou Y, Lee EJ (2008) The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects. Br J Clin Pharmacol 66:233\u2013239","journal-title":"Br J Clin Pharmacol"},{"key":"9_CR2_9","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/jps.21860","volume":"99","author":"KK Adkison","year":"2010","unstructured":"Adkison KK, Vaidya SS, Lee DY, Koo SH, Li L, Mehta AA, Gross AS, Polli JW, Humphreys JE, Lou Y, Lee EJ (2010) Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. J Pharm Sci 99:1046\u20131062","journal-title":"J Pharm Sci"},{"key":"9_CR3_9","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1158\/0008-5472.CAN-04-1817","volume":"65","author":"A Ahmed-Belkacem","year":"2005","unstructured":"Ahmed-Belkacem A, Pozza A, Munoz-Martinez F, Bates SE, Castanys S, Gamarro F, Di Pietro A, Perez-Victoria JM (2005) Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. Cancer Res 65:4852\u20134860","journal-title":"Cancer Res"},{"key":"9_CR4_9","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1128\/AAC.46.6.1831-1836.2002","volume":"46","author":"J Alcorn","year":"2002","unstructured":"Alcorn J, McNamara PJ (2002) Acyclovir, ganciclovir, and zidovudine transfer into rat milk. Antimicrob Agents Chemother 46:1831\u20131836","journal-title":"Antimicrob Agents Chemother"},{"key":"9_CR5_9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1124\/jpet.102.038315","volume":"303","author":"J Alcorn","year":"2002","unstructured":"Alcorn J, Lu X, Moscow JA, McNamara PJ (2002) Transporter gene expression in lactating and nonlactating human mammary epithelial cells using real-time reverse transcription-polymerase chain reaction. J Pharmacol Exp Ther 303:487\u2013496","journal-title":"J Pharmacol Exp Ther"},{"key":"9_CR6_9","first-page":"4237","volume":"59","author":"JD Allen","year":"1999","unstructured":"Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH (1999) The mouse Bcrp1\/Mxr\/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 59:4237\u20134241","journal-title":"Cancer Res"},{"key":"9_CR7_9","first-page":"417","volume":"1","author":"JD Allen","year":"2002","unstructured":"Allen JD, van Loevezijn A, Lakhai JM, van der Valk V, van Tellingen O, Reid G, Schellens JH, Koomen GJ, Schinkel AH (2002) Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 1:417\u2013425","journal-title":"Mol Cancer Ther"},{"key":"9_CR8_9","first-page":"1339","volume":"63","author":"JD Allen","year":"2003","unstructured":"Allen JD, van Dort SC, Buitelaar M, van Tellingen O, Schinkel AH (2003) Mouse breast cancer resistance protein (Bcrp1\/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res 63:1339\u20131344","journal-title":"Cancer Res"},{"key":"9_CR9_9","first-page":"5337","volume":"58","author":"R Allikmets","year":"1998","unstructured":"Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M (1998) A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 58:5337\u20135339","journal-title":"Cancer Res"},{"key":"9_CR10_9","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1186\/bcr660","volume":"5","author":"AJ Alvi","year":"2003","unstructured":"Alvi AJ, Clayton H, Joshi C, Enver T, Ashworth A, Vivanco MM, Dale TC, Smalley MJ (2003) Functional and molecular characterisation of mammary side population cells. Breast Cancer Res 5:R1\u2013R8","journal-title":"Breast Cancer Res"},{"key":"9_CR11_9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11095-008-9738-5","volume":"26","author":"R An","year":"2009","unstructured":"An R, Hagiya Y, Tamura A, Li S, Saito H, Tokushima D, Ishikawa T (2009) Cellular phototoxicity evoked through the inhibition of human ABC transporter ABCG2 by cyclin-dependent kinase inhibitors in vitro. Pharm Res 26:449\u2013458","journal-title":"Pharm Res"},{"key":"9_CR12_9","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1186\/1471-2407-9-407","volume":"9","author":"V Andersen","year":"2009","unstructured":"Andersen V, Ostergaard M, Christensen J, Overvad K, Tjonneland A, Vogel U (2009) Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer 9:407","journal-title":"BMC Cancer"},{"key":"9_CR13_9","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1124\/dmd.107.014969","volume":"35","author":"T Ando","year":"2007","unstructured":"Ando T, Kusuhara H, Merino G, Alvarez AI, Schinkel AH, Sugiyama Y (2007) Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones. Drug Metab Dispos 35:1873\u20131879","journal-title":"Drug Metab Dispos"},{"key":"9_CR14_9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.placenta.2008.12.012","volume":"30","author":"K Annola","year":"2009","unstructured":"Annola K, Heikkinen AT, Partanen H, Woodhouse H, Segerback D, Vahakangas K (2009) Transplacental transfer of nitrosodimethylamine in perfused human placenta. Placenta 30:277\u2013283","journal-title":"Placenta"},{"key":"9_CR15_9","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1016\/j.bbamem.2008.08.010","volume":"1778","author":"A Apati","year":"2008","unstructured":"Apati A, Orban TI, Varga N, Nemeth A, Schamberger A, Krizsik V, Erdelyi-Belle B, Homolya L, Varady G, Padanyi R, Karaszi E, Kemna EW, Nemet K, Sarkadi B (2008) High level functional expression of the ABCG2 multidrug transporter in undifferentiated human embryonic stem cells. Biochim Biophys Acta 1778:2700\u20132709","journal-title":"Biochim Biophys Acta"},{"key":"9_CR16_9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0928-0987(03)00038-1","volume":"18","author":"G Backstrom","year":"2003","unstructured":"Backstrom G, Taipalensuu J, Melhus H, Brandstrom H, Svensson AC, Artursson P, Kindmark A (2003) Genetic variation in the ATP-binding cassette transporter gene ABCG2 (BCRP) in a Swedish population. Eur J Pharm Sci 18:359\u2013364","journal-title":"Eur J Pharm Sci"},{"key":"9_CR17_9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0167-4781(01)00270-6","volume":"1520","author":"KJ Bailey-Dell","year":"2001","unstructured":"Bailey-Dell KJ, Hassel B, Doyle LA, Ross DD (2001) Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochim Biophys Acta 1520:234\u2013241","journal-title":"Biochim Biophys Acta"},{"key":"9_CR18_9","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1167\/iovs.08-2356","volume":"50","author":"MM Balla","year":"2009","unstructured":"Balla MM, Vemuganti GK, Kannabiran C, Honavar SG, Murthy R (2009) Phenotypic characterization of retinoblastoma for the presence of putative cancer stem-like cell markers by flow cytometry. Invest Ophthalmol Vis Sci 50:1506\u20131514","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"9_CR19_9","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.1158\/1078-0432.CCR-04-0795","volume":"10","author":"Z Benderra","year":"2004","unstructured":"Benderra Z, Faussat AM, Sayada L, Perrot JY, Chaoui D, Marie JP, Legrand O (2004) Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 10:7896\u20137902","journal-title":"Clin Cancer Res"},{"key":"9_CR20_9","doi-asserted-by":"crossref","first-page":"7764","DOI":"10.1158\/1078-0432.CCR-04-1895","volume":"11","author":"Z Benderra","year":"2005","unstructured":"Benderra Z, Faussat AM, Sayada L, Perrot JY, Tang R, Chaoui D, Morjani H, Marzac C, Marie JP, Legrand O (2005) MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res 11:7764\u20137772","journal-title":"Clin Cancer Res"},{"key":"9_CR21_9","doi-asserted-by":"crossref","first-page":"16281","DOI":"10.1073\/pnas.0905653106","volume":"106","author":"G Bertolini","year":"2009","unstructured":"Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, Roz E, Caserini R, Lo VS, Camerini T, Mariani L, Delia D, Calabro E, Pastorino U, Sozzi G (2009) Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 106:16281\u201316286","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9_CR22_9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1349-7006.2006.00164.x","volume":"97","author":"Y Bessho","year":"2006","unstructured":"Bessho Y, Oguri T, Achiwa H, Muramatsu H, Maeda H, Niimi T, Sato S, Ueda R (2006) Role of ABCG2 as a biomarker for predicting resistance to CPT-11\/SN-38 in lung cancer. Cancer Sci 97:192\u2013198","journal-title":"Cancer Sci"},{"key":"9_CR23_9","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/j.1471-4159.2007.04808.x","volume":"102","author":"S Bihorel","year":"2007","unstructured":"Bihorel S, Camenisch G, Lemaire M, Scherrmann JM (2007) Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood\u2013brain barrier. J Neurochem 102:1749\u20131757","journal-title":"J Neurochem"},{"key":"9_CR24_9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2165\/00129785-200505020-00005","volume":"5","author":"TM Bosch","year":"2005","unstructured":"Bosch TM, Kjellberg LM, Bouwers A, Koeleman BP, Schellens JH, Beijnen JH, Smits PH, Meijerman I (2005) Detection of single nucleotide polymorphisms in the ABCG2 gene in a Dutch population. Am J Pharmacogenomics 5:123\u2013131","journal-title":"Am J Pharmacogenomics"},{"key":"9_CR25_9","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1021\/jm050705h","volume":"48","author":"A Boumendjel","year":"2005","unstructured":"Boumendjel A, Nicolle E, Moraux T, Gerby B, Blanc M, Ronot X, Boutonnat J (2005) Piperazinobenzopyranones and phenalkylaminobenzopyranones: potent inhibitors of breast cancer resistance protein (ABCG2). J Med Chem 48:7275\u20137281","journal-title":"J Med Chem"},{"key":"9_CR26_9","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1016\/j.bmc.2007.02.017","volume":"15","author":"A Boumendjel","year":"2007","unstructured":"Boumendjel A, Macalou S, Ahmed-Belkacem A, Blanc M, Di Pietro A (2007) Acridone derivatives: design, synthesis, and inhibition of breast cancer resistance protein ABCG2. Bioorg Med Chem 15:2892\u20132897","journal-title":"Bioorg Med Chem"},{"key":"9_CR27_9","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s00280-006-0230-9","volume":"58","author":"E Bram","year":"2006","unstructured":"Bram E, Ifergan I, Shafran A, Berman B, Jansen G, Assaraf YG (2006) Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol 58:826\u2013834","journal-title":"Cancer Chemother Pharmacol"},{"key":"9_CR28_9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bcp.2007.03.028","volume":"74","author":"EE Bram","year":"2007","unstructured":"Bram EE, Ifergan I, Grimberg M, Lemke K, Skladanowski A, Assaraf YG (2007) C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells. Biochem Pharmacol 74:41\u201353","journal-title":"Biochem Pharmacol"},{"key":"9_CR29_9","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1593\/neo.91314","volume":"11","author":"EE Bram","year":"2009","unstructured":"Bram EE, Stark M, Raz S, Assaraf YG (2009) Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance. Neoplasia 11:1359\u20131370","journal-title":"Neoplasia"},{"key":"9_CR30_9","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1158\/0008-5472.CAN-03-4062","volume":"64","author":"P Breedveld","year":"2004","unstructured":"Breedveld P, Zelcer N, Pluim D, Sonmezer O, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P, Schellens JH (2004) Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug\u2013drug interactions. Cancer Res 64:5804\u20135811","journal-title":"Cancer Res"},{"key":"9_CR31_9","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1158\/0008-5472.CAN-04-2416","volume":"65","author":"P Breedveld","year":"2005","unstructured":"Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, Schellens JH (2005) The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 65:2577\u20132582","journal-title":"Cancer Res"},{"key":"9_CR32_9","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/mol.106.028167","volume":"71","author":"P Breedveld","year":"2007","unstructured":"Breedveld P, Pluim D, Cipriani G, Dahlhaus F, van Eijndhoven MA, de Wolf CJ, Kuil A, Beijnen JH, Scheffer GL, Jansen G, Borst P, Schellens JH (2007) The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol 71:240\u2013249","journal-title":"Mol Pharmacol"},{"key":"9_CR33_9","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/sj.leu.2404638","volume":"21","author":"C Brendel","year":"2007","unstructured":"Brendel C, Scharenberg C, Dohse M, Robey RW, Bates SE, Shukla S, Ambudkar SV, Wang Y, Wennemuth G, Burchert A, Boudriot U, Neubauer A (2007) Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 21:1267\u20131275","journal-title":"Leukemia"},{"key":"9_CR34_9","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1182\/blood-2004-04-1398","volume":"104","author":"H Burger","year":"2004","unstructured":"Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, Nooter K (2004) Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2 drug pump. Blood 104:2940\u20132942","journal-title":"Blood"},{"key":"9_CR35_9","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/ijc.20032","volume":"109","author":"L Candeil","year":"2004","unstructured":"Candeil L, Gourdier I, Peyron D, Vezzio N, Copois V, Bibeau F, Orsetti B, Scheffer GL, Ychou M, Khan QA, Pommier Y, Pau B, Martineau P, Del Rio M (2004) ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. Int J Cancer 109:848\u2013854","journal-title":"Int J Cancer"},{"key":"9_CR36_9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1067\/mcp.2001.114164","volume":"69","author":"I Cascorbi","year":"2001","unstructured":"Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169\u2013174","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"9_CR37_9","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/jhg.2009.80","volume":"54","author":"PC Cha","year":"2009","unstructured":"Cha PC, Mushiroda T, Zembutsu H, Harada H, Shinoda N, Kawamoto S, Shimoyama R, Nishidate T, Furuhata T, Sasaki K, Hirata K, Nakamura Y (2009) Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression. J Hum Genet 54(10):572\u2013580","journal-title":"J Hum Genet"},{"key":"9_CR38_9","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1158\/1535-7163.MCT-06-0087","volume":"5","author":"W Chearwae","year":"2006","unstructured":"Chearwae W, Shukla S, Limtrakul P, Ambudkar SV (2006) Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. Mol Cancer Ther 5:1995\u20132006","journal-title":"Mol Cancer Ther"},{"key":"9_CR39_9","doi-asserted-by":"crossref","first-page":"10073","DOI":"10.1016\/S0021-9258(19)38781-2","volume":"265","author":"YN Chen","year":"1990","unstructured":"Chen YN, Mickley LA, Schwartz AM, Acton EM, Hwang JL, Fojo AT (1990) Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem 265:10073\u201310080","journal-title":"J Biol Chem"},{"key":"9_CR40_9","first-page":"4048","volume":"63","author":"ZS Chen","year":"2003","unstructured":"Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, Kruh GD (2003) Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 63:4048\u20134054","journal-title":"Cancer Res"},{"key":"9_CR41_9","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/01.mlg.0000195075.14093.fb","volume":"116","author":"JS Chen","year":"2006","unstructured":"Chen JS, Pardo FS, Wang-Rodriguez J, Chu TS, Lopez JP, Aguilera J, Altuna X, Weisman RA, Ongkeko WM (2006) EGFR regulates the side population in head and neck squamous cell carcinoma. Laryngoscope 116:401\u2013406","journal-title":"Laryngoscope"},{"key":"9_CR42_9","doi-asserted-by":"crossref","first-page":"e2637","DOI":"10.1371\/journal.pone.0002637","volume":"3","author":"YC Chen","year":"2008","unstructured":"Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, Hung SC, Chang YL, Tsai ML, Lee YY, Ku HH, Chiou SH (2008) Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS ONE 3:e2637","journal-title":"PLoS ONE"},{"key":"9_CR43_9","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1124\/jpet.109.154781","volume":"330","author":"Y Chen","year":"2009","unstructured":"Chen Y, Agarwal S, Shaik NM, Chen C, Yang Z, Elmquist WF (2009) P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. J Pharmacol Exp Ther 330:956\u2013963","journal-title":"J Pharmacol Exp Ther"},{"key":"9_CR44_9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11010-007-9570-y","volume":"306","author":"M Christgen","year":"2007","unstructured":"Christgen M, Ballmaier M, Bruchhardt H, von Wasielewski R, Kreipe H, Lehmann U (2007) Identification of a distinct side population of cancer cells in the Cal-51 human breast carcinoma cell line. Mol Cell Biochem 306:201\u2013212","journal-title":"Mol Cell Biochem"},{"key":"9_CR45_9","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1158\/0008-5472.CAN-03-2033","volume":"64","author":"S Cisternino","year":"2004","unstructured":"Cisternino S, Mercier C, Bourasset F, Roux F, Scherrmann JM (2004) Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood\u2013brain barrier. Cancer Res 64:3296\u20133301","journal-title":"Cancer Res"},{"key":"9_CR46_9","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/01.fpc.0000172241.42546.d3","volume":"15","author":"S Colombo","year":"2005","unstructured":"Colombo S, Soranzo N, Rotger M, Sprenger R, Bleiber G, Furrer H, Buclin T, Goldstein D, Decosterd L, Telenti A (2005) Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenet Genomics 15:599\u2013608","journal-title":"Pharmacogenet Genomics"},{"key":"9_CR47_9","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1097\/00001756-200211150-00014","volume":"13","author":"HC Cooray","year":"2002","unstructured":"Cooray HC, Blackmore CG, Maskell L, Barrand MA (2002) Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 13:2059\u20132063","journal-title":"Neuroreport"},{"key":"9_CR48_9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.bbrc.2004.03.040","volume":"317","author":"HC Cooray","year":"2004","unstructured":"Cooray HC, Janvilisri T, van Veen HW, Hladky SB, Barrand MA (2004) Interaction of the breast cancer resistance protein with plant polyphenols. Biochem Biophys Res Commun 317:269\u2013275","journal-title":"Biochem Biophys Res Commun"},{"key":"9_CR49_9","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/jnci\/djj469","volume":"98","author":"G Cusatis","year":"2006","unstructured":"Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A, Baker SD (2006) Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 98:1739\u20131742","journal-title":"J Natl Cancer Inst"},{"key":"9_CR50_9","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1124\/jpet.109.160564","volume":"331","author":"LH Cygalova","year":"2009","unstructured":"Cygalova LH, Hofman J, Ceckova M, Staud F (2009) Transplacental pharmacokinetics of glyburide, rhodamine 123, and BODIPY FL prazosin: effect of drug efflux transporters and lipid solubility. J Pharmacol Exp Ther 331:1118\u20131125","journal-title":"J Pharmacol Exp Ther"},{"key":"9_CR51_9","doi-asserted-by":"crossref","first-page":"7905","DOI":"10.1158\/0008-5472.CAN-08-0499","volume":"68","author":"CL Dai","year":"2008","unstructured":"Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, Ashby CR Jr, Huang Y, Robey RW, Liang YJ, Chen LM, Shi CJ, Ambudkar SV, Chen ZS, Fu LW (2008) Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 68:7905\u20137914","journal-title":"Cancer Res"},{"key":"9_CR52_9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.canlet.2009.01.027","volume":"279","author":"CL Dai","year":"2009","unstructured":"Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW (2009) Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett 279:74\u201383","journal-title":"Cancer Lett"},{"key":"9_CR53_9","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1158\/1078-0432.CCR-04-0144","volume":"10","author":"FA de Jong","year":"2004","unstructured":"de Jong FA, Marsh S, Mathijssen RH, King C, Verweij J, Sparreboom A, McLeod HL (2004) ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res 10:5889\u20135894","journal-title":"Clin Cancer Res"},{"key":"9_CR54_9","doi-asserted-by":"crossref","first-page":"6440","DOI":"10.1158\/1078-0432.CCR-07-1335","volume":"13","author":"NA de Vries","year":"2007","unstructured":"de Vries NA, Zhao J, Kroon E, Buckle T, Beijnen JH, van Tellingen O (2007) P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res 13:6440\u20136449","journal-title":"Clin Cancer Res"},{"key":"9_CR55_9","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0140-6736(08)61343-4","volume":"372","author":"A Dehghan","year":"2008","unstructured":"Dehghan A, Kottgen A, Yang Q, Hwang SJ, Kao WL, Rivadeneira F, Boerwinkle E, Levy D, Hofman A, Astor BC, Benjamin EJ, van Duijn CM, Witteman JC, Coresh J, Fox CS (2008) Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 372:1953\u20131961","journal-title":"Lancet"},{"key":"9_CR56_9","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/01.ju.0000074710.96154.c9","volume":"170","author":"JE Diestra","year":"2003","unstructured":"Diestra JE, Condom E, Del Muro XG, Scheffer GL, Perez J, Zurita AJ, Munoz-Segui J, Vigues F, Scheper RJ, Capella G, Germa-Lluch JR, Izquierdo MA (2003) Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and clinical implications. J Urol 170:1383\u20131387","journal-title":"J Urol"},{"key":"9_CR57_9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.lfs.2010.02.012","volume":"86","author":"XW Ding","year":"2010","unstructured":"Ding XW, Wu JH, Jiang CP (2010) ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci 86:631\u2013637","journal-title":"Life Sci"},{"key":"9_CR58_9","doi-asserted-by":"crossref","first-page":"7340","DOI":"10.1038\/sj.onc.1206938","volume":"22","author":"LA Doyle","year":"2003","unstructured":"Doyle LA, Ross DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340\u20137358","journal-title":"Oncogene"},{"key":"9_CR59_9","doi-asserted-by":"crossref","first-page":"15665","DOI":"10.1073\/pnas.95.26.15665","volume":"95","author":"LA Doyle","year":"1998","unstructured":"Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 95:15665\u201315670","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9_CR60_9","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/carcin\/bgi139","volume":"26","author":"B Ebert","year":"2005","unstructured":"Ebert B, Seidel A, Lampen A (2005) Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. Carcinogenesis 26:1754\u20131763","journal-title":"Carcinogenesis"},{"key":"9_CR61_9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0006-8993(03)02401-6","volume":"971","author":"T Eisenblatter","year":"2003","unstructured":"Eisenblatter T, Huwel S, Galla HJ (2003) Characterisation of the brain multidrug resistance protein (BMDP\/ABCG2\/BCRP) expressed at the blood\u2013brain barrier. Brain Res 971:221\u2013231","journal-title":"Brain Res"},{"key":"9_CR62_9","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1158\/0008-5472.CAN-04-3303","volume":"65","author":"NB Elkind","year":"2005","unstructured":"Elkind NB, Szentpetery Z, Apati A, Ozvegy-Laczka C, Varady G, Ujhelly O, Szabo K, Homolya L, Varadi A, Buday L, Keri G, Nemet K, Sarkadi B (2005) Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res 65:1770\u20131777","journal-title":"Cancer Res"},{"key":"9_CR63_9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ibd.20030","volume":"13","author":"G Englund","year":"2007","unstructured":"Englund G, Jacobson A, Rorsman F, Artursson P, Kindmark A, Ronnblom A (2007) Efflux transporters in ulcerative colitis: decreased expression of BCRP (ABCG2) and Pgp (ABCB1). Inflamm Bowel Dis 13:291\u2013297","journal-title":"Inflamm Bowel Dis"},{"key":"9_CR64_9","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1124\/mol.107.034751","volume":"72","author":"J Enokizono","year":"2007","unstructured":"Enokizono J, Kusuhara H, Sugiyama Y (2007a) Effect of breast cancer resistance protein (Bcrp\/Abcg2) on the disposition of phytoestrogens. Mol Pharmacol 72:967\u2013975","journal-title":"Mol Pharmacol"},{"key":"9_CR65_9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/dmd.106.012567","volume":"35","author":"J Enokizono","year":"2007","unstructured":"Enokizono J, Kusuhara H, Sugiyama Y (2007b) Involvement of breast cancer resistance protein (BCRP\/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect. Drug Metab Dispos 35:209\u2013214","journal-title":"Drug Metab Dispos"},{"key":"9_CR66_9","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1124\/dmd.107.019257","volume":"36","author":"J Enokizono","year":"2008","unstructured":"Enokizono J, Kusuhara H, Ose A, Schinkel AH, Sugiyama Y (2008) Quantitative investigation of the role of breast cancer resistance protein (Bcrp\/Abcg2) in limiting brain and testis penetration of xenobiotic compounds. Drug Metab Dispos 36:995\u20131002","journal-title":"Drug Metab Dispos"},{"key":"9_CR67_9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cellimm.2007.02.007","volume":"244","author":"DJ Erdelyi","year":"2006","unstructured":"Erdelyi DJ, Kamory E, Zalka A, Semsei AF, Csokay B, Andrikovics H, Tordai A, Borgulya G, Magyarosy E, Galantai I, Fekete G, Falus A, Szalai C, Kovacs GT (2006) The role of ABC-transporter gene polymorphisms in chemotherapy induced immunosuppression, a retrospective study in childhood acute lymphoblastic leukaemia. Cell Immunol 244:121\u2013124","journal-title":"Cell Immunol"},{"key":"9_CR68_9","first-page":"1068","volume":"8","author":"IF Faneyte","year":"2002","unstructured":"Faneyte IF, Kristel PM, Maliepaard M, Scheffer GL, Scheper RJ, Schellens JH, van De Vijver MJ (2002) Expression of the breast cancer resistance protein in breast cancer. Clin Cancer Res 8:1068\u20131074","journal-title":"Clin Cancer Res"},{"key":"9_CR69_9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/cyto.b.20403","volume":"74","author":"LL Figueiredo-Pontes","year":"2008","unstructured":"Figueiredo-Pontes LL, Pintao MC, Oliveira LC, Dalmazzo LF, Jacomo RH, Garcia AB, Falcao RP, Rego EM (2008) Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia. Cytometry B Clin Cytom 74:163\u2013168","journal-title":"Cytometry B Clin Cytom"},{"key":"9_CR70_9","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1211\/jpp.57.10.0009","volume":"57","author":"H Fujino","year":"2005","unstructured":"Fujino H, Saito T, Ogawa S, Kojima J (2005) Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol 57:1305\u20131311","journal-title":"J Pharm Pharmacol"},{"key":"9_CR71_9","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s11095-008-9752-7","volume":"26","author":"T Furukawa","year":"2009","unstructured":"Furukawa T, Wakabayashi K, Tamura A, Nakagawa H, Morishima Y, Osawa Y, Ishikawa T (2009) Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations. Pharm Res 26:469\u2013479","journal-title":"Pharm Res"},{"key":"9_CR72_9","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1208\/s12248-009-9132-1","volume":"11","author":"YA Gandhi","year":"2009","unstructured":"Gandhi YA, Morris ME (2009) Structure-activity relationships and quantitative structure-activity relationships for breast cancer resistance protein (ABCG2). AAPS J 11:541\u2013552","journal-title":"AAPS J"},{"key":"9_CR73_9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clpt.2006.05.003","volume":"80","author":"ER Gardner","year":"2006","unstructured":"Gardner ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, Guetens G, Prenen H, de Jong FA, Baker SD, Bates SE, Figg WD, Verweij J, Sparreboom A, Nooter K (2006) Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther 80:192\u2013201","journal-title":"Clin Pharmacol Ther"},{"key":"9_CR74_9","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1111\/j.1464-410X.2008.07913.x","volume":"102","author":"ER Gardner","year":"2008","unstructured":"Gardner ER, Ahlers CM, Shukla S, Sissung TM, Ockers SB, Price DK, Hamada A, Robey RW, Steinberg SM, Ambudkar SV, Dahut WL, Figg WD (2008) Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival. BJU Int 102:1694\u20131699","journal-title":"BJU Int"},{"key":"9_CR75_9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1756-9966-28-99","volume":"28","author":"ER Gardner","year":"2009","unstructured":"Gardner ER, Smith NF, Figg WD, Sparreboom A (2009) Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice. J Exp Clin Cancer Res 28:99","journal-title":"J Exp Clin Cancer Res"},{"key":"9_CR76_9","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.placenta.2005.11.012","volume":"27","author":"C Gedeon","year":"2006","unstructured":"Gedeon C, Behravan J, Koren G, Piquette-Miller M (2006) Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta 27:1096\u20131102","journal-title":"Placenta"},{"key":"9_CR77_9","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1124\/dmd.108.020974","volume":"36","author":"N Giri","year":"2008","unstructured":"Giri N, Shaik N, Pan G, Terasaki T, Mukai C, Kitagaki S, Miyakoshi N, Elmquist WF (2008) Investigation of the role of breast cancer resistance protein (Bcrp\/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse. Drug Metab Dispos 36:1476\u20131484","journal-title":"Drug Metab Dispos"},{"key":"9_CR78_9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10637-007-9093-0","volume":"26","author":"MK Gounder","year":"2008","unstructured":"Gounder MK, Nazar AS, Saleem A, Pungaliya P, Kulkarni D, Versace R, Rubin EH (2008) Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan. Invest New Drugs 26:205\u2013213","journal-title":"Invest New Drugs"},{"key":"9_CR79_9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/03602530801952617","volume":"40","author":"U Gradhand","year":"2008","unstructured":"Gradhand U, Kim RB (2008) Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2). Drug Metab Rev 40:317\u2013354","journal-title":"Drug Metab Rev"},{"key":"9_CR80_9","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1124\/jpet.104.065342","volume":"310","author":"A Gupta","year":"2004","unstructured":"Gupta A, Zhang Y, Unadkat JD, Mao Q (2004) HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP\/ABCG2). J Pharmacol Exp Ther 310:334\u2013341","journal-title":"J Pharmacol Exp Ther"},{"key":"9_CR81_9","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00280-005-0173-6","volume":"58","author":"A Gupta","year":"2006","unstructured":"Gupta A, Dai Y, Vethanayagam RR, Hebert MF, Thummel KE, Unadkat JD, Ross DD, Mao Q (2006) Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol 58:374\u2013383","journal-title":"Cancer Chemother Pharmacol"},{"key":"9_CR82_9","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.bcp.2005.05.031","volume":"70","author":"H Gutmann","year":"2005","unstructured":"Gutmann H, Hruz P, Zimmermann C, Beglinger C, Drewe J (2005) Distribution of breast cancer resistance protein (BCRP\/ABCG2) mRNA expression along the human GI tract. Biochem Pharmacol 70:695\u2013699","journal-title":"Biochem Pharmacol"},{"key":"9_CR83_9","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1124\/jpet.103.055574","volume":"307","author":"A Hamada","year":"2003","unstructured":"Hamada A, Miyano H, Watanabe H, Saito H (2003) Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther 307:824\u2013828","journal-title":"J Pharmacol Exp Ther"},{"key":"9_CR84_9","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/cncr.22760","volume":"110","author":"JY Han","year":"2007","unstructured":"Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY, Lee JE, Lee DH, Kim HT, Lee JS (2007) Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 110:138\u2013147","journal-title":"Cancer"},{"key":"9_CR85_9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.lungcan.2007.07.019","volume":"59","author":"JY Han","year":"2008","unstructured":"Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, Kim HT, Lee JS (2008a) Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer 59:69\u201375","journal-title":"Lung Cancer"},{"key":"9_CR86_9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejps.2008.06.001","volume":"35","author":"Y Han","year":"2008","unstructured":"Han Y, Riwanto M, Go ML, Ee PL (2008b) Modulation of breast cancer resistance protein (BCRP\/ABCG2) by non-basic chalcone analogues. Eur J Pharm Sci 35:30\u201341","journal-title":"Eur J Pharm Sci"},{"key":"9_CR87_9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.lungcan.2007.12.003","volume":"63","author":"JY Han","year":"2009","unstructured":"Han JY, Lim HS, Park YH, Lee SY, Lee JS (2009) Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer 63:115\u2013120","journal-title":"Lung Cancer"},{"key":"9_CR88_9","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1476-5381.2009.00383.x","volume":"158","author":"C Hegedus","year":"2009","unstructured":"Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L, Keri G, Katona M, Takats Z, Varadi A, Szakacs G, Sarkadi B (2009a) Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol 158:1153\u20131164","journal-title":"Br J Pharmacol"},{"key":"9_CR89_9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.addr.2008.09.007","volume":"61","author":"C Hegedus","year":"2009","unstructured":"Hegedus C, Szakacs G, Homolya L, Orban TI, Telbisz A, Jani M, Sarkadi B (2009b) Ins and outs of the ABCG2 multidrug transporter: an update on in vitro functional assays. Adv Drug Deliv Rev 61:47\u201356","journal-title":"Adv Drug Deliv Rev"},{"key":"9_CR90_9","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/1087057105284576","volume":"11","author":"CJ Henrich","year":"2006","unstructured":"Henrich CJ, Bokesch HR, Dean M, Bates SE, Robey RW, Goncharova EI, Wilson JA, McMahon JB (2006) A high-throughput cell-based assay for inhibitors of ABCG2 activity. J Biomol Screen 11:176\u2013183","journal-title":"J Biomol Screen"},{"key":"9_CR91_9","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1124\/mol.105.014019","volume":"68","author":"M Hirano","year":"2005","unstructured":"Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, Sugiyama Y (2005) Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 68:800\u2013807","journal-title":"Mol Pharmacol"},{"key":"9_CR92_9","doi-asserted-by":"crossref","first-page":"14228","DOI":"10.1073\/pnas.0400067101","volume":"101","author":"C Hirschmann-Jax","year":"2004","unstructured":"Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA, Brenner MK (2004) A distinct \u201cside population\u201d of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 101:14228\u201314233","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9_CR93_9","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-07-5095","volume":"14","author":"DK Hiwase","year":"2008","unstructured":"Hiwase DK, Saunders V, Hewett D, Frede A, Zrim S, Dang P, Eadie L, To LB, Melo J, Kumar S, Hughes TP, White DL (2008) Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 14:3881\u20133888","journal-title":"Clin Cancer Res"},{"key":"9_CR94_9","doi-asserted-by":"crossref","first-page":"4827","DOI":"10.1158\/0008-5472.CAN-06-3557","volume":"67","author":"MM Ho","year":"2007","unstructured":"Ho MM, Ng AV, Lam S, Hung JY (2007a) Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 67:4827\u20134833","journal-title":"Cancer Res"},{"key":"9_CR95_9","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/FPC.0b013e3280ef698f","volume":"17","author":"RH Ho","year":"2007","unstructured":"Ho RH, Choi L, Lee W, Mayo G, Schwarz UI, Tirona RG, Bailey DG, Michael SC, Kim RB (2007b) Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics 17:647\u2013656","journal-title":"Pharmacogenet Genomics"},{"key":"9_CR96_9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.exphem.2007.11.014","volume":"36","author":"MM Ho","year":"2008","unstructured":"Ho MM, Hogge DE, Ling V (2008) MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia. Exp Hematol 36:433\u2013442","journal-title":"Exp Hematol"},{"key":"9_CR97_9","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/sj.bjp.0707467","volume":"152","author":"ML Holland","year":"2007","unstructured":"Holland ML, Lau DT, Allen JD, Arnold JC (2007) The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. Br J Pharmacol 152:815\u2013824","journal-title":"Br J Pharmacol"},{"key":"9_CR98_9","first-page":"6635","volume":"61","author":"Y Honjo","year":"2001","unstructured":"Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van de Laar A, Litman T, Dean M, Bates SE (2001) Acquired mutations in the MXR\/BCRP\/ABCP gene alter substrate specificity in MXR\/BCRP\/ABCP-overexpressing cells. Cancer Res 61:6635\u20136639","journal-title":"Cancer Res"},{"key":"9_CR99_9","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4161\/cbt.322","volume":"1","author":"Y Honjo","year":"2002","unstructured":"Honjo Y, Morisaki K, Huff LM, Robey RW, Hung J, Dean M, Bates SE (2002) Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR\/BCRP\/ABCP1). Cancer Biol Ther 1:696\u2013702","journal-title":"Cancer Biol Ther"},{"key":"9_CR100_9","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1158\/0008-5472.CAN-03-3344","volume":"64","author":"PJ Houghton","year":"2004","unstructured":"Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E, Traxler P (2004) Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 64:2333\u20132337","journal-title":"Cancer Res"},{"key":"9_CR101_9","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/carcin\/bgm113","volume":"28","author":"LL Hu","year":"2007","unstructured":"Hu LL, Wang XX, Chen X, Chang J, Li C, Zhang Y, Yang J, Jiang W, Zhuang SM (2007) BCRP gene polymorphisms are associated with susceptibility and survival of diffuse large B-cell lymphoma. Carcinogenesis 28:1740\u20131744","journal-title":"Carcinogenesis"},{"key":"9_CR102_9","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1093\/carcin\/bgn223","volume":"29","author":"C Hu","year":"2008","unstructured":"Hu C, Li H, Li J, Zhu Z, Yin S, Hao X, Yao M, Zheng S, Gu J (2008) Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis 29:2289\u20132297","journal-title":"Carcinogenesis"},{"key":"9_CR103_9","doi-asserted-by":"crossref","first-page":"6062","DOI":"10.1158\/1078-0432.CCR-09-0048","volume":"15","author":"S Hu","year":"2009","unstructured":"Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD (2009) Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 15:6062\u20136069","journal-title":"Clin Cancer Res"},{"key":"9_CR104_9","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1124\/dmd.105.007534","volume":"34","author":"L Huang","year":"2006","unstructured":"Huang L, Wang Y, Grimm S (2006) ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos 34:738\u2013742","journal-title":"Drug Metab Dispos"},{"key":"9_CR105_9","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1089\/scd.2008.0033","volume":"18","author":"D Huang","year":"2009","unstructured":"Huang D, Gao Q, Guo L, Zhang C, Jiang W, Li H, Wang J, Han X, Shi Y, Lu SH (2009) Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines. Stem Cells Dev 18:465\u2013473","journal-title":"Stem Cells Dev"},{"key":"9_CR106_9","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s10620-005-2933-x","volume":"50","author":"SZ Hussain","year":"2005","unstructured":"Hussain SZ, Strom SC, Kirby MR, Burns S, Langemeijer S, Ueda T, Hsieh M, Tisdale JF (2005) Side population cells derived from adult human liver generate hepatocyte-like cells in vitro. Dig Dis Sci 50:1755\u20131763","journal-title":"Dig Dis Sci"},{"key":"9_CR107_9","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/sj.clpt.6100190","volume":"82","author":"I Ieiri","year":"2007","unstructured":"Ieiri I, Suwannakul S, Maeda K, Uchimaru H, Hashimoto K, Kimura M, Fujino H, Hirano M, Kusuhara H, Irie S, Higuchi S, Sugiyama Y (2007) SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 82:541\u2013547","journal-title":"Clin Pharmacol Ther"},{"key":"9_CR108_9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s100380200041","volume":"47","author":"A Iida","year":"2002","unstructured":"Iida A, Saito S, Sekine A, Mishima C, Kitamura Y, Kondo K, Harigae S, Osawa S, Nakamura Y (2002) Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8. J Hum Genet 47:285\u2013310","journal-title":"J Hum Genet"},{"key":"9_CR109_9","first-page":"611","volume":"1","author":"Y Imai","year":"2002","unstructured":"Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T, Miki Y, Sugimoto Y (2002) C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 1:611\u2013616","journal-title":"Mol Cancer Ther"},{"key":"9_CR110_9","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00001813-200006000-00005","volume":"11","author":"M Ishii","year":"2000","unstructured":"Ishii M, Iwahana M, Mitsui I, Minami M, Imagawa S, Tohgo A, Ejima A (2000) Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6. Anticancer Drugs 11:353\u2013362","journal-title":"Anticancer Drugs"},{"key":"9_CR111_9","first-page":"5","volume":"8","author":"T Ishikawa","year":"2009","unstructured":"Ishikawa T, Nakagawa H (2009) Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics. J Exp Ther Oncol 8:5\u201324","journal-title":"J Exp Ther Oncol"},{"key":"9_CR112_9","doi-asserted-by":"crossref","first-page":"212","DOI":"10.2133\/dmpk.18.212","volume":"18","author":"M Itoda","year":"2003","unstructured":"Itoda M, Saito Y, Shirao K, Minami H, Ohtsu A, Yoshida T, Saijo N, Suzuki H, Sugiyama Y, Ozawa S, Sawada J (2003) Eight novel single nucleotide polymorphisms in ABCG2\/BCRP in Japanese cancer patients administered irinotacan. Drug Metab Pharmacokinet 18:212\u2013217","journal-title":"Drug Metab Pharmacokinet"},{"key":"9_CR113_9","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1111\/j.1349-7006.2007.00541.x","volume":"98","author":"SR Jada","year":"2007","unstructured":"Jada SR, Lim R, Wong CI, Shu X, Lee SC, Zhou Q, Goh BC, Chowbay B (2007) Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci 98:1461\u20131467","journal-title":"Cancer Sci"},{"key":"9_CR114_9","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1093\/carcin\/15.11.2479","volume":"15","author":"IM Jagerstad","year":"1994","unstructured":"Jagerstad IM, Johansson MA, Karlsson AA, Skog KI, Oskarsson A, Palminger-Hallen I, Ivhed R, Brittebo EB (1994) Dose-dependent milk transfer and tissue distribution of the food mutagen PhIP in rats and their suckling pups. Carcinogenesis 15:2479\u20132484","journal-title":"Carcinogenesis"},{"key":"9_CR115_9","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.bbrc.2006.04.152","volume":"345","author":"J Jin","year":"2006","unstructured":"Jin J, Shahi S, Kang HK, van Veen HW, Fan TP (2006) Metabolites of ginsenosides as novel BCRP inhibitors. Biochem Biophys Res Commun 345:1308\u20131314","journal-title":"Biochem Biophys Res Commun"},{"key":"9_CR116_9","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1093\/jnci\/92.20.1651","volume":"92","author":"JW Jonker","year":"2000","unstructured":"Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, Schinkel AH (2000) Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92:1651\u20131656","journal-title":"J Natl Cancer Inst"},{"key":"9_CR117_9","doi-asserted-by":"crossref","first-page":"15649","DOI":"10.1073\/pnas.202607599","volume":"99","author":"JW Jonker","year":"2002","unstructured":"Jonker JW, Buitelaar M, Wagenaar E, van der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, Beijnen JH, Schinkel AH (2002) The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A 99:15649\u201315654","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9_CR118_9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nm1186","volume":"11","author":"JW Jonker","year":"2005","unstructured":"Jonker JW, Merino G, Musters S, van Herwaarden AE, Bolscher E, Wagenaar E, Mesman E, Dale TC, Schinkel AH (2005) The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med 11:127\u2013129","journal-title":"Nat Med"},{"key":"9_CR119_9","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s11095-008-9532-4","volume":"25","author":"J Kamiie","year":"2008","unstructured":"Kamiie J, Ohtsuki S, Iwase R, Ohmine K, Katsukura Y, Yanai K, Sekine Y, Uchida Y, Ito S, Terasaki T (2008) Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC\/MS\/MS method combined with novel in-silico peptide selection criteria. Pharm Res 25:1469\u20131483","journal-title":"Pharm Res"},{"key":"9_CR120_9","first-page":"1059","volume":"29","author":"K Katayama","year":"2009","unstructured":"Katayama K, Shibata K, Mitsuhashi J, Noguchi K, Sugimoto Y (2009a) Pharmacological interplay between breast cancer resistance protein and gefitinib in epidermal growth factor receptor signaling. Anticancer Res 29:1059\u20131065","journal-title":"Anticancer Res"},{"key":"9_CR121_9","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1111\/j.1349-7006.2009.01288.x","volume":"100","author":"R Katayama","year":"2009","unstructured":"Katayama R, Koike S, Sato S, Sugimoto Y, Tsuruo T, Fujita N (2009b) Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2\/BCRP-mediated drug export. Cancer Sci 100:2060\u20132068","journal-title":"Cancer Sci"},{"key":"9_CR122_9","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1006\/bbrc.2001.4267","volume":"280","author":"S Kawabata","year":"2001","unstructured":"Kawabata S, Oka M, Shiozawa K, Tsukamoto K, Nakatomi K, Soda H, Fukuda M, Ikegami Y, Sugahara K, Yamada Y, Kamihira S, Doyle LA, Ross DD, Kohno S (2001) Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun 280:1216\u20131223","journal-title":"Biochem Biophys Res Commun"},{"key":"9_CR123_9","first-page":"3052","volume":"9","author":"S Kawabata","year":"2003","unstructured":"Kawabata S, Oka M, Soda H, Shiozawa K, Nakatomi K, Tsurutani J, Nakamura Y, Doi S, Kitazaki T, Sugahara K, Yamada Y, Kamihira S, Kohno S (2003) Expression and functional analyses of breast cancer resistance protein in lung cancer. Clin Cancer Res 9:3052\u20133057","journal-title":"Clin Cancer Res"},{"key":"9_CR124_9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.18433\/J3V30R","volume":"12","author":"A Kawase","year":"2009","unstructured":"Kawase A, Matsumoto Y, Hadano M, Ishii Y, Iwaki M (2009) Differential effects of chrysin on nitrofurantoin pharmacokinetics mediated by intestinal breast cancer resistance protein in rats and mice. J Pharm Pharm Sci 12:150\u2013163","journal-title":"J Pharm Pharm Sci"},{"key":"9_CR125_9","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/(SICI)1097-0215(19970529)71:5<817::AID-IJC20>3.0.CO;2-3","volume":"71","author":"U Kellner","year":"1997","unstructured":"Kellner U, Hutchinson L, Seidel A, Lage H, Danks MK, Dietel M, Kaufmann SH (1997) Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein. Int J Cancer 71:817\u2013824","journal-title":"Int J Cancer"},{"key":"9_CR126_9","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/pgs.09.85","volume":"10","author":"JE Keskitalo","year":"2009","unstructured":"Keskitalo JE, Pasanen MK, Neuvonen PJ, Niemi M (2009a) Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics 10:1617\u20131624","journal-title":"Pharmacogenomics"},{"key":"9_CR127_9","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/clpt.2009.79","volume":"86","author":"JE Keskitalo","year":"2009","unstructured":"Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M (2009b) ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 86:197\u2013203","journal-title":"Clin Pharmacol Ther"},{"key":"9_CR128_9","first-page":"22","volume":"8","author":"M Kim","year":"2002","unstructured":"Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, Gong M, Dean M, Sharp JG, Cowan K (2002) The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res 8:22\u201328","journal-title":"Clin Cancer Res"},{"key":"9_CR129_9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2125.2007.02944.x","volume":"64","author":"HS Kim","year":"2007","unstructured":"Kim HS, Sunwoo YE, Ryu JY, Kang HJ, Jung HE, Song IS, Kim EY, Shim JC, Shon JH, Shin JG (2007) The effect of ABCG2 V12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine. Br J Clin Pharmacol 64:645\u2013654","journal-title":"Br J Clin Pharmacol"},{"key":"9_CR130_9","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/j.1349-7006.2008.00985.x","volume":"99","author":"IS Kim","year":"2008","unstructured":"Kim IS, Kim HG, Kim DC, Eom HS, Kong SY, Shin HJ, Hwang SH, Lee EY, Lee GW (2008) ABCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide\/doxorubicin\/vincristine\/prednisone chemotherapy. Cancer Sci 99:2496\u20132501","journal-title":"Cancer Sci"},{"key":"9_CR131_9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.lungcan.2008.10.008","volume":"65","author":"YH Kim","year":"2009","unstructured":"Kim YH, Ishii G, Goto K, Ota S, Kubota K, Murata Y, Mishima M, Saijo N, Nishiwaki Y, Ochiai A (2009) Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. Lung Cancer 65:105\u2013111","journal-title":"Lung Cancer"},{"key":"9_CR132_9","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1136\/ard.2007.086264","volume":"68","author":"E Kis","year":"2009","unstructured":"Kis E, Nagy T, Jani M, Molnar E, Janossy J, Ujhellyi O, Nemet K, Heredi-Szabo K, Krajcsi P (2009) Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance. Ann Rheum Dis 68:1201\u20131207","journal-title":"Ann Rheum Dis"},{"key":"9_CR133_9","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1124\/dmd.108.021410","volume":"36","author":"S Kitamura","year":"2008","unstructured":"Kitamura S, Maeda K, Wang Y, Sugiyama Y (2008) Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 36:2014\u20132023","journal-title":"Drug Metab Dispos"},{"key":"9_CR134_9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1124\/dmd.104.001628","volume":"33","author":"D Kobayashi","year":"2005","unstructured":"Kobayashi D, Ieiri I, Hirota T, Takane H, Maegawa S, Kigawa J, Suzuki H, Nanba E, Oshimura M, Terakawa N, Otsubo K, Mine K, Sugiyama Y (2005) Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 33:94\u2013101","journal-title":"Drug Metab Dispos"},{"key":"9_CR135_9","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1124\/dmd.104.002261","volume":"33","author":"D Kolwankar","year":"2005","unstructured":"Kolwankar D, Glover DD, Ware JA, Tracy TS (2005) Expression and function of ABCB1 and ABCG2 in human placental tissue. Drug Metab Dispos 33:524\u2013529","journal-title":"Drug Metab Dispos"},{"key":"9_CR136_9","doi-asserted-by":"crossref","first-page":"e1000504","DOI":"10.1371\/journal.pgen.1000504","volume":"5","author":"M Kolz","year":"2009","unstructured":"Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, Perola M, Mangino M, Albrecht E, Wallace C, Farrall M, Johansson A, Nyholt DR, Aulchenko Y, Beckmann JS, Bergmann S, Bochud M, Brown M, Campbell H, Connell J, Dominiczak A, Homuth G, Lamina C, McCarthy MI, Meitinger T, Mooser V, Munroe P, Nauck M, Peden J, Prokisch H, Salo P, Salomaa V, Samani NJ, Schlessinger D, Uda M, Volker U, Waeber G, Waterworth D, Wang-Sattler R, Wright AF, Adamski J, Whitfield JB, Gyllensten U, Wilson JF, Rudan I, Pramstaller P, Watkins H, Doering A, Wichmann HE, Spector TD, Peltonen L, Volzke H, Nagaraja R, Vollenweider P, Caulfield M, Illig T, Gieger C (2009) Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 5:e1000504","journal-title":"PLoS Genet"},{"key":"9_CR137_9","first-page":"2827","volume":"61","author":"H Komatani","year":"2001","unstructured":"Komatani H, Kotani H, Hara Y, Nakagawa R, Matsumoto M, Arakawa H, Nishimura S (2001) Identification of breast cancer resistant protein\/mitoxantrone resistance\/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. Cancer Res 61:2827\u20132832","journal-title":"Cancer Res"},{"key":"9_CR138_9","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1023\/B:PHAM.0000045245.21637.d4","volume":"21","author":"C Kondo","year":"2004","unstructured":"Kondo C, Suzuki H, Itoda M, Ozawa S, Sawada J, Kobayashi D, Ieiri I, Mine K, Ohtsubo K, Sugiyama Y (2004) Functional analysis of SNPs variants of BCRP\/ABCG2. Pharm Res 21:1895\u20131903","journal-title":"Pharm Res"},{"key":"9_CR139_9","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s11095-005-2487-9","volume":"22","author":"C Kondo","year":"2005","unstructured":"Kondo C, Onuki R, Kusuhara H, Suzuki H, Suzuki M, Okudaira N, Kojima M, Ishiwata K, Jonker JW, Sugiyama Y (2005) Lack of improvement of oral absorption of ME3277 by prodrug formation is ascribed to the intestinal efflux mediated by breast cancer resistant protein (BCRP\/ABCG2). Pharm Res 22:613\u2013618","journal-title":"Pharm Res"},{"key":"9_CR140_9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/ijc.21187","volume":"117","author":"Y Korenaga","year":"2005","unstructured":"Korenaga Y, Naito K, Okayama N, Hirata H, Suehiro Y, Hamanaka Y, Matsuyama H, Hinoda Y (2005) Association of the BCRP C421A polymorphism with nonpapillary renal cell carcinoma. Int J Cancer 117:431\u2013434","journal-title":"Int J Cancer"},{"key":"9_CR141_9","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1532\/IJH97.E0624","volume":"86","author":"M Kourti","year":"2007","unstructured":"Kourti M, Vavatsi N, Gombakis N, Sidi V, Tzimagiorgis G, Papageorgiou T, Koliouskas D, Athanassiadou F (2007) Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia. Int J Hematol 86:166\u2013173","journal-title":"Int J Hematol"},{"key":"9_CR142_9","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ajog.2005.12.005","volume":"195","author":"J Kraemer","year":"2006","unstructured":"Kraemer J, Klein J, Lubetsky A, Koren G (2006) Perfusion studies of glyburide transfer across the human placenta: implications for fetal safety. Am J Obstet Gynecol 195:270\u2013274","journal-title":"Am J Obstet Gynecol"},{"key":"9_CR143_9","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1146\/annurev.pharmtox.46.120604.141238","volume":"46","author":"P Krishnamurthy","year":"2006","unstructured":"Krishnamurthy P, Schuetz JD (2006) Role of ABCG2\/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol 46:381\u2013410","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"9_CR144_9","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1158\/0008-5472.CAN-07-6790","volume":"68","author":"P Krishnamurthy","year":"2008","unstructured":"Krishnamurthy P, Schwab M, Takenaka K, Nachagari D, Morgan J, Leslie M, Du W, Boyd K, Cheok M, Nakauchi H, Marzolini C, Kim RB, Poonkuzhali B, Schuetz E, Evans W, Relling M, Schuetz JD (2008) Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res 68:4983\u20134989","journal-title":"Cancer Res"},{"key":"9_CR145_9","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1200\/JCO.2002.12.116","volume":"20","author":"CM Kruijtzer","year":"2002","unstructured":"Kruijtzer CM, Beijnen JH, Rosing H, Bokkel Huinink WW, Schot M, Jewell RC, Paul EM, Schellens JH (2002) Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 20:2943\u20132950","journal-title":"J Clin Oncol"},{"key":"9_CR146_9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1124\/dmd.108.023200","volume":"37","author":"JS Lagas","year":"2009","unstructured":"Lagas JS, van der Kruijssen CM, van de Wetering K, Beijnen JH, Schinkel AH (2009a) Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos 37:129\u2013136","journal-title":"Drug Metab Dispos"},{"key":"9_CR147_9","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/1078-0432.CCR-08-2253","volume":"15","author":"JS Lagas","year":"2009","unstructured":"Lagas JS, van Waterschoot RA, van Tilburg VA, Hillebrand MJ, Lankheet N, Rosing H, Beijnen JH, Schinkel AH (2009b) Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin Cancer Res 15:2344\u20132351","journal-title":"Clin Cancer Res"},{"key":"9_CR148_9","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1124\/mi.9.3.7","volume":"9","author":"JS Lagas","year":"2009","unstructured":"Lagas JS, Vlaming ML, Schinkel AH (2009c) Pharmacokinetic assessment of multiple ATP-binding cassette transporters: the power of combination knockout mice. Mol Interv 9:136\u2013145","journal-title":"Mol Interv"},{"issue":"2","key":"9_CR149_9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1158\/1535-7163.MCT-09-0663","volume":"9","author":"JS Lagas","year":"2010","unstructured":"Lagas JS, van Waterschoot RA, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH (2010) Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther 9(2):319\u2013326","journal-title":"Mol Cancer Ther"},{"key":"9_CR150_9","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1349-7006.2008.00744.x","volume":"99","author":"S Lal","year":"2008","unstructured":"Lal S, Wong ZW, Sandanaraj E, Xiang X, Ang PC, Lee EJ, Chowbay B (2008) Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 99:816\u2013823","journal-title":"Cancer Sci"},{"key":"9_CR151_9","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0006-291X(02)00275-9","volume":"293","author":"A Lechner","year":"2002","unstructured":"Lechner A, Leech CA, Abraham EJ, Nolan AL, Habener JF (2002) Nestin-positive progenitor cells derived from adult human pancreatic islets of Langerhans contain side population (SP) cells defined by expression of the ABCG2 (BCRP1) ATP-binding cassette transporter. Biochem Biophys Res Commun 293:670\u2013674","journal-title":"Biochem Biophys Res Commun"},{"key":"9_CR152_9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1124\/jpet.104.073320","volume":"312","author":"YJ Lee","year":"2005","unstructured":"Lee YJ, Kusuhara H, Jonker JW, Schinkel AH, Sugiyama Y (2005) Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood\u2013brain barrier: a minor role of breast cancer resistance protein. J Pharmacol Exp Ther 312:44\u201352","journal-title":"J Pharmacol Exp Ther"},{"key":"9_CR153_9","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1124\/dmd.106.012302","volume":"35","author":"SS Lee","year":"2007","unstructured":"Lee SS, Jeong HE, Yi JM, Jung HJ, Jang JE, Kim EY, Lee SJ, Shin JG (2007) Identification and functional assessment of BCRP polymorphisms in a Korean population. Drug Metab Dispos 35:623\u2013632","journal-title":"Drug Metab Dispos"},{"key":"9_CR154_9","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1158\/0008-5472.CAN-05-2915","volume":"66","author":"M Leggas","year":"2006","unstructured":"Leggas M, Panetta JC, Zhuang Y, Schuetz JD, Johnston B, Bai F, Sorrentino B, Zhou S, Houghton PJ, Stewart CF (2006) Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res 66:4802\u20134807","journal-title":"Cancer Res"},{"key":"9_CR155_9","doi-asserted-by":"crossref","first-page":"432","DOI":"10.4161\/cbt.6.3.3763","volume":"6","author":"J Li","year":"2007","unstructured":"Li J, Cusatis G, Brahmer J, Sparreboom A, Robey RW, Bates SE, Hidalgo M, Baker SD (2007) Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther 6:432\u2013438","journal-title":"Cancer Biol Ther"},{"key":"9_CR156_9","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejps.2008.06.008","volume":"35","author":"M Li","year":"2008","unstructured":"Li M, Yuan H, Li N, Song G, Zheng Y, Baratta M, Hua F, Thurston A, Wang J, Lai Y (2008) Identification of interspecies difference in efflux transporters of hepatocytes from dog, rat, monkey and human. Eur J Pharm Sci 35:114\u2013126","journal-title":"Eur J Pharm Sci"},{"key":"9_CR157_9","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3816\/CLC.2009.n.078","volume":"10","author":"J Li","year":"2009","unstructured":"Li J, Li ZN, Du YJ, Li XQ, Bao QL, Chen P (2009a) Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival. Clin Lung Cancer 10:414\u2013421","journal-title":"Clin Lung Cancer"},{"key":"9_CR158_9","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1021\/ac8024009","volume":"81","author":"N Li","year":"2009","unstructured":"Li N, Palandra J, Nemirovskiy OV, Lai Y (2009b) LC-MS\/MS mediated absolute quantification and comparison of bile salt export pump and breast cancer resistance protein in livers and hepatocytes across species. Anal Chem 81:2251\u20132259","journal-title":"Anal Chem"},{"key":"9_CR159_9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11010-006-9302-8","volume":"296","author":"P Limtrakul","year":"2007","unstructured":"Limtrakul P, Chearwae W, Shukla S, Phisalphong C, Ambudkar SV (2007) Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol Cell Biochem 296:85\u201395","journal-title":"Mol Cell Biochem"},{"key":"9_CR160_9","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1242\/jcs.113.11.2011","volume":"113","author":"T Litman","year":"2000","unstructured":"Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, Miyake K, Resau JH, Bates SE (2000) The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113:2011\u20132021","journal-title":"J Cell Sci"},{"key":"9_CR161_9","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1158\/1078-0432.CCR-06-1599","volume":"13","author":"W Liu","year":"2007","unstructured":"Liu W, Baer MR, Bowman MJ, Pera P, Zheng X, Morgan J, Pandey RA, Oseroff AR (2007) The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin Cancer Res 13:2463\u20132470","journal-title":"Clin Cancer Res"},{"key":"9_CR162_9","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/sj.bjc.6604185","volume":"98","author":"MR Loebinger","year":"2008","unstructured":"Loebinger MR, Giangreco A, Groot KR, Prichard L, Allen K, Simpson C, Bazley L, Navani N, Tibrewal S, Davies D, Janes SM (2008) Squamous cell cancers contain a side population of stem-like cells that are made chemosensitive by ABC transporter blockade. Br J Cancer 98:380\u2013387","journal-title":"Br J Cancer"},{"key":"9_CR163_9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2133\/dmpk.21.109","volume":"21","author":"K Maekawa","year":"2006","unstructured":"Maekawa K, Itoda M, Sai K, Saito Y, Kaniwa N, Shirao K, Hamaguchi T, Kunitoh H, Yamamoto N, Tamura T, Minami H, Kubota K, Ohtsu A, Yoshida T, Saijo N, Kamatani N, Ozawa S, Sawada J (2006) Genetic variation and haplotype structure of the ABC transporter gene ABCG2 in a Japanese population. Drug Metab Pharmacokinet 21:109\u2013121","journal-title":"Drug Metab Pharmacokinet"},{"key":"9_CR164_9","doi-asserted-by":"crossref","first-page":"e4235","DOI":"10.1371\/journal.pone.0004235","volume":"4","author":"YY Mahller","year":"2009","unstructured":"Mahller YY, Williams JP, Baird WH, Mitton B, Grossheim J, Saeki Y, Cancelas JA, Ratner N, Cripe TP (2009) Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS ONE 4:e4235","journal-title":"PLoS ONE"},{"key":"9_CR165_9","first-page":"4559","volume":"59","author":"M Maliepaard","year":"1999","unstructured":"Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, Schellens JH (1999) Overexpression of the BCRP\/MXR\/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 59:4559\u20134563","journal-title":"Cancer Res"},{"key":"9_CR166_9","first-page":"3458","volume":"61","author":"M Maliepaard","year":"2001","unstructured":"Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, Schellens JH (2001a) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458\u20133464","journal-title":"Cancer Res"},{"key":"9_CR167_9","first-page":"935","volume":"7","author":"M Maliepaard","year":"2001","unstructured":"Maliepaard M, van Gastelen MA, Tohgo A, Hausheer FH, van Waardenburg RC, de Jong LA, Pluim D, Beijnen JH, Schellens JH (2001b) Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res 7:935\u2013941","journal-title":"Clin Cancer Res"},{"key":"9_CR168_9","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1158\/1535-7163.MCT-07-0461","volume":"6","author":"S Marchetti","year":"2007","unstructured":"Marchetti S, Oostendorp RL, Pluim D, van Eijndhoven M, van Tellingen O, Schinkel AH, Versace R, Beijnen JH, Mazzanti R, Schellens JH (2007) In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2. Mol Cancer Ther 6:3307\u20133313","journal-title":"Mol Cancer Ther"},{"key":"9_CR169_9","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/sj.tpj.6500434","volume":"7","author":"S Marsh","year":"2007","unstructured":"Marsh S, Somlo G, Li X, Frankel P, King CR, Shannon WD, McLeod HL, Synold TW (2007) Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J 7:362\u2013365","journal-title":"Pharmacogenomics J"},{"key":"9_CR170_9","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.4161\/cc.8.7.8043","volume":"8","author":"G Mathew","year":"2009","unstructured":"Mathew G, Timm EA Jr, Sotomayor P, Godoy A, Montecinos VP, Smith GJ, Huss WJ (2009) ABCG2-mediated DyeCycle Violet efflux defined side population in benign and malignant prostate. Cell Cycle 8:1053\u20131061","journal-title":"Cell Cycle"},{"key":"9_CR171_9","doi-asserted-by":"crossref","first-page":"R963","DOI":"10.1152\/ajpregu.00173.2005","volume":"289","author":"AA Mathias","year":"2005","unstructured":"Mathias AA, Hitti J, Unadkat JD (2005) P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages. Am J Physiol Regul Integr Comp Physiol 289:R963\u2013R969","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"9_CR172_9","first-page":"3246","volume":"9","author":"RH Mathijssen","year":"2003","unstructured":"Mathijssen RH, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J, Sparreboom A, McLeod HL (2003) Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 9:3246\u20133253","journal-title":"Clin Cancer Res"},{"key":"9_CR173_9","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1124\/jpet.105.085589","volume":"314","author":"S Matsushima","year":"2005","unstructured":"Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y (2005) Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)\/multidrug resistance-associated protein 2, OATP1B1\/multidrug resistance 1, and OATP1B1\/breast cancer resistance protein. J Pharmacol Exp Ther 314:1059\u20131067","journal-title":"J Pharmacol Exp Ther"},{"key":"9_CR174_9","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/ijc.22391","volume":"120","author":"HP McDowell","year":"2007","unstructured":"McDowell HP, Meco D, Riccardi A, Tanno B, Berardi AC, Raschella G, Riccardi R, Dominici C (2007) Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models. Int J Cancer 120:1141\u20131149","journal-title":"Int J Cancer"},{"key":"9_CR175_9","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/S0022-3565(25)13115-7","volume":"277","author":"PJ McNamara","year":"1996","unstructured":"McNamara PJ, Meece JA, Paxton E (1996) Active transport of cimetidine and ranitidine into the milk of Sprague Dawley rats. J Pharmacol Exp Ther 277:1615\u20131621","journal-title":"J Pharmacol Exp Ther"},{"key":"9_CR176_9","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1124\/dmd.104.003319","volume":"33","author":"G Merino","year":"2005","unstructured":"Merino G, Jonker JW, Wagenaar E, Pulido MM, Molina AJ, Alvarez AI, Schinkel AH (2005a) Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP\/ABCG2). Drug Metab Dispos 33:614\u2013618","journal-title":"Drug Metab Dispos"},{"key":"9_CR177_9","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1124\/mol.104.010439","volume":"67","author":"G Merino","year":"2005","unstructured":"Merino G, Jonker JW, Wagenaar E, van Herwaarden AE, Schinkel AH (2005b) The breast cancer resistance protein (BCRP\/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol 67:1758\u20131764","journal-title":"Mol Pharmacol"},{"key":"9_CR178_9","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1124\/mol.105.011080","volume":"67","author":"G Merino","year":"2005","unstructured":"Merino G, van Herwaarden AE, Wagenaar E, Jonker JW, Schinkel AH (2005c) Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP\/ABCG2) in liver. Mol Pharmacol 67:1765\u20131771","journal-title":"Mol Pharmacol"},{"key":"9_CR179_9","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1124\/dmd.105.008219","volume":"34","author":"G Merino","year":"2006","unstructured":"Merino G, Alvarez AI, Pulido MM, Molina AJ, Schinkel AH, Prieto JG (2006) Breast cancer resistance protein (BCRP\/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos 34:690\u2013695","journal-title":"Drug Metab Dispos"},{"key":"9_CR180_9","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1124\/dmd.105.007591","volume":"34","author":"HE Meyer zu Schwabedissen","year":"2006","unstructured":"Meyer zu Schwabedissen HE, Grube M, Dreisbach A, Jedlitschky G, Meissner K, Linnemann K, Fusch C, Ritter CA, Volker U, Kroemer HK (2006) Epidermal growth factor-mediated activation of the map kinase cascade results in altered expression and function of ABCG2 (BCRP). Drug Metab Dispos 34:524\u2013533","journal-title":"Drug Metab Dispos"},{"key":"9_CR181_9","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1158\/1078-0432.CCR-0914-3","volume":"10","author":"H Minderman","year":"2004","unstructured":"Minderman H, O'Loughlin KL, Pendyala L, Baer MR (2004) VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin Cancer Res 10:1826\u20131834","journal-title":"Clin Cancer Res"},{"key":"9_CR182_9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/leu.2008.246","volume":"23","author":"N Misaghian","year":"2009","unstructured":"Misaghian N, Ligresti G, Steelman LS, Bertrand FE, Basecke J, Libra M, Nicoletti F, Stivala F, Milella M, Tafuri A, Cervello M, Martelli AM, McCubrey JA (2009) Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia 23:25\u201342","journal-title":"Leukemia"},{"key":"9_CR183_9","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1042\/bj20030150","volume":"373","author":"H Mitomo","year":"2003","unstructured":"Mitomo H, Kato R, Ito A, Kasamatsu S, Ikegami Y, Kii I, Kudo A, Kobatake E, Sumino Y, Ishikawa T (2003) A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport. Biochem J 373:767\u2013774","journal-title":"Biochem J"},{"key":"9_CR184_9","first-page":"8","volume":"59","author":"K Miyake","year":"1999","unstructured":"Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, Bates SE (1999) Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 59:8\u201313","journal-title":"Cancer Res"},{"key":"9_CR185_9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ijc.11669","volume":"109","author":"S Mizuarai","year":"2004","unstructured":"Mizuarai S, Aozasa N, Kotani H (2004) Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer 109:238\u2013246","journal-title":"Int J Cancer"},{"key":"9_CR186_9","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.ejca.2007.01.017","volume":"43","author":"E Monzani","year":"2007","unstructured":"Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C, Gritti A, Piccinini A, Porro D, Santinami M, Invernici G, Parati E, Alessandri G, La Porta CA (2007) Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 43:935\u2013946","journal-title":"Eur J Cancer"},{"key":"9_CR187_9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00280-004-0931-x","volume":"56","author":"K Morisaki","year":"2005","unstructured":"Morisaki K, Robey RW, Ozvegy-Laczka C, Honjo Y, Polgar O, Steadman K, Sarkadi B, Bates SE (2005) Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol 56:161\u2013172","journal-title":"Cancer Chemother Pharmacol"},{"key":"9_CR188_9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.taap.2008.07.006","volume":"232","author":"P Myllynen","year":"2008","unstructured":"Myllynen P, Kummu M, Kangas T, Ilves M, Immonen E, Rysa J, Pirila R, Lastumaki A, Vahakangas KH (2008) ABCG2\/BCRP decreases the transfer of a food-born chemical carcinogen, 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine (PhIP) in perfused term human placenta. Toxicol Appl Pharmacol 232:210\u2013217","journal-title":"Toxicol Appl Pharmacol"},{"key":"9_CR189_9","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s00280-006-0212-y","volume":"58","author":"S Nagashima","year":"2006","unstructured":"Nagashima S, Soda H, Oka M, Kitazaki T, Shiozawa K, Nakamura Y, Takemura M, Yabuuchi H, Fukuda M, Tsukamoto K, Kohno S (2006) BCRP\/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer. Cancer Chemother Pharmacol 58:594\u2013600","journal-title":"Cancer Chemother Pharmacol"},{"key":"9_CR190_9","first-page":"6175","volume":"52","author":"M Nakagawa","year":"1992","unstructured":"Nakagawa M, Schneider E, Dixon KH, Horton J, Kelley K, Morrow C, Cowan KH (1992) Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer Res 52:6175\u20136181","journal-title":"Cancer Res"},{"key":"9_CR191_9","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1042\/BJ20071229","volume":"411","author":"H Nakagawa","year":"2008","unstructured":"Nakagawa H, Tamura A, Wakabayashi K, Hoshijima K, Komada M, Yoshida T, Kometani S, Matsubara T, Mikuriya K, Ishikawa T (2008) Ubiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2. Biochem J 411:623\u2013631","journal-title":"Biochem J"},{"key":"9_CR192_9","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1158\/0008-5472.CAN-03-2417","volume":"65","author":"Y Nakamura","year":"2005","unstructured":"Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, Ikegami Y, Tsurutani J, Nakatomi K, Kitazaki T, Doi S, Yoshida H, Kohno S (2005) Gefitinib (\u201cIressa\u201d, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein\/ABCG2-mediated drug resistance. Cancer Res 65:1541\u20131546","journal-title":"Cancer Res"},{"key":"9_CR193_9","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1124\/mol.64.6.1452","volume":"64","author":"T Nakanishi","year":"2003","unstructured":"Nakanishi T, Doyle LA, Hassel B, Wei Y, Bauer KS, Wu S, Pumplin DW, Fang HB, Ross DD (2003a) Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis. Mol Pharmacol 64:1452\u20131462","journal-title":"Mol Pharmacol"},{"key":"9_CR194_9","first-page":"3320","volume":"9","author":"T Nakanishi","year":"2003","unstructured":"Nakanishi T, Karp JE, Tan M, Doyle LA, Peters T, Yang W, Wei D, Ross DD (2003b) Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients. Clin Cancer Res 9:3320\u20133328","journal-title":"Clin Cancer Res"},{"key":"9_CR195_9","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/ijc.10608","volume":"101","author":"K Nakayama","year":"2002","unstructured":"Nakayama K, Kanzaki A, Ogawa K, Miyazaki K, Neamati N, Takebayashi Y (2002) Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP. Int J Cancer 101:488\u2013495","journal-title":"Int J Cancer"},{"key":"9_CR196_9","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/147323000903700304","volume":"37","author":"ZF Ning","year":"2009","unstructured":"Ning ZF, Huang YJ, Lin TX, Zhou YX, Jiang C, Xu KW, Huang H, Yin XB, Huang J (2009) Subpopulations of stem-like cells in side population cells from the human bladder transitional cell cancer cell line T24. J Int Med Res 37:621\u2013630","journal-title":"J Int Med Res"},{"key":"9_CR197_9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.addr.2008.07.003","volume":"61","author":"K Noguchi","year":"2009","unstructured":"Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y (2009) Functions of the breast cancer resistance protein (BCRP\/ABCG2) in chemotherapy. Adv Drug Deliv Rev 61:26\u201333","journal-title":"Adv Drug Deliv Rev"},{"key":"9_CR198_9","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1196\/annals.1302.015","volume":"1015","author":"H Oh","year":"2004","unstructured":"Oh H, Chi X, Bradfute SB, Mishina Y, Pocius J, Michael LH, Behringer RR, Schwartz RJ, Entman ML, Schneider MD (2004) Cardiac muscle plasticity in adult and embryo by heart-derived progenitor cells. Ann NY Acad Sci 1015:182\u2013189","journal-title":"Ann NY Acad Sci"},{"key":"9_CR199_9","doi-asserted-by":"crossref","first-page":"18700","DOI":"10.1073\/pnas.0704472104","volume":"104","author":"M Ono","year":"2007","unstructured":"Ono M, Maruyama T, Masuda H, Kajitani T, Nagashima T, Arase T, Ito M, Ohta K, Uchida H, Asada H, Yoshimura Y, Okano H, Matsuzaki Y (2007) Side population in human uterine myometrium displays phenotypic and functional characteristics of myometrial stem cells. Proc Natl Acad Sci U S A 104:18700\u201318705","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9_CR200_9","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/978-1-4615-1371-1_68","volume":"501","author":"CY Oo","year":"2001","unstructured":"Oo CY, Paxton EW, McNamara PJ (2001) Active transport of nitrofurantoin into rat milk. Adv Exp Med Biol 501:547\u2013552","journal-title":"Adv Exp Med Biol"},{"key":"9_CR201_9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10637-008-9138-z","volume":"27","author":"RL Oostendorp","year":"2009","unstructured":"Oostendorp RL, Buckle T, Beijnen JH, van Tellingen O, Schellens JH (2009) The effect of P-gp (Mdr1a\/1b), BCRP (Bcrp1) and P-gp\/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs 27:31\u201340","journal-title":"Invest New Drugs"},{"key":"9_CR202_9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2008.07.014","volume":"64","author":"S Ota","year":"2009","unstructured":"Ota S, Ishii G, Goto K, Kubota K, Kim YH, Kojika M, Murata Y, Yamazaki M, Nishiwaki Y, Eguchi K, Ochiai A (2009) Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer 64:98\u2013104","journal-title":"Lung Cancer"},{"key":"9_CR203_9","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1124\/mol.65.6.1485","volume":"65","author":"C Ozvegy-Laczka","year":"2004","unstructured":"Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, Keri G, Orfi L, Nemet K, Sarkadi B (2004) High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 65:1485\u20131495","journal-title":"Mol Pharmacol"},{"key":"9_CR204_9","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1124\/dmd.106.014274","volume":"35","author":"G Pan","year":"2007","unstructured":"Pan G, Giri N, Elmquist WF (2007) Abcg2\/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine. Drug Metab Dispos 35:1165\u20131173","journal-title":"Drug Metab Dispos"},{"key":"9_CR205_9","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1124\/jpet.104.073916","volume":"312","author":"P Pavek","year":"2005","unstructured":"Pavek P, Merino G, Wagenaar E, Bolscher E, Novotna M, Jonker JW, Schinkel AH (2005) Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4, 5-b)pyridine, and transport of cimetidine. J Pharmacol Exp Ther 312:144\u2013152","journal-title":"J Pharmacol Exp Ther"},{"key":"9_CR206_9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00280-006-0357-8","volume":"60","author":"A Pawarode","year":"2007","unstructured":"Pawarode A, Shukla S, Minderman H, Fricke SM, Pinder EM, O'Loughlin KL, Ambudkar SV, Baer MR (2007) Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins. Cancer Chemother Pharmacol 60:179\u2013188","journal-title":"Cancer Chemother Pharmacol"},{"key":"9_CR207_9","doi-asserted-by":"crossref","first-page":"e5676","DOI":"10.1371\/journal.pone.0005676","volume":"4","author":"H Peng","year":"2009","unstructured":"Peng H, Dong Z, Qi J, Yang Y, Liu Y, Li Z, Xu J, Zhang JT (2009) A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy. PLoS ONE 4:e5676","journal-title":"PLoS ONE"},{"key":"9_CR208_9","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.placenta.2008.05.001","volume":"29","author":"E Pollex","year":"2008","unstructured":"Pollex E, Lubetsky A, Koren G (2008) The role of placental breast cancer resistance protein in the efflux of glyburide across the human placenta. Placenta 29:743\u2013747","journal-title":"Placenta"},{"key":"9_CR209_9","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1124\/dmd.108.024646","volume":"37","author":"JW Polli","year":"2009","unstructured":"Polli JW, Olson KL, Chism JP, John-Williams LS, Yeager RL, Woodard SM, Otto V, Castellino S, Demby VE (2009) An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab Dispos 37:439\u2013442","journal-title":"Drug Metab Dispos"},{"key":"9_CR210_9","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1124\/dmd.107.018366","volume":"36","author":"B Poonkuzhali","year":"2008","unstructured":"Poonkuzhali B, Lamba J, Strom S, Sparreboom A, Thummel K, Watkins P, Schuetz E (2008) Association of breast cancer resistance protein\/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms. Drug Metab Dispos 36:780\u2013795","journal-title":"Drug Metab Dispos"},{"key":"9_CR211_9","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2885.2006.00744.x","volume":"29","author":"MM Pulido","year":"2006","unstructured":"Pulido MM, Molina AJ, Merino G, Mendoza G, Prieto JG, Alvarez AI (2006) Interaction of enrofloxacin with breast cancer resistance protein (BCRP\/ABCG2): influence of flavonoids and role in milk secretion in sheep. J Vet Pharmacol Ther 29:279\u2013287","journal-title":"J Vet Pharmacol Ther"},{"key":"9_CR212_9","first-page":"5850","volume":"58","author":"SK Rabindran","year":"1998","unstructured":"Rabindran SK, He H, Singh M, Brown E, Collins KI, Annable T, Greenberger LM (1998) Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res 58:5850\u20135858","journal-title":"Cancer Res"},{"key":"9_CR213_9","first-page":"47","volume":"60","author":"SK Rabindran","year":"2000","unstructured":"Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM (2000) Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 60:47\u201350","journal-title":"Cancer Res"},{"key":"9_CR214_9","first-page":"3228","volume":"63","author":"R Rajendra","year":"2003","unstructured":"Rajendra R, Gounder MK, Saleem A, Schellens JH, Ross DD, Bates SE, Sinko P, Rubin EH (2003) Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. Cancer Res 63:3228\u20133233","journal-title":"Cancer Res"},{"key":"9_CR215_9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0005-2736(01)00308-X","volume":"1512","author":"RW Robey","year":"2001","unstructured":"Robey RW, Honjo Y, van de Laar A, Miyake K, Regis JT, Litman T, Bates SE (2001a) A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim Biophys Acta 1512:171\u2013182","journal-title":"Biochim Biophys Acta"},{"key":"9_CR216_9","first-page":"145","volume":"7","author":"RW Robey","year":"2001","unstructured":"Robey RW, Medina-Perez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD, Bates SE (2001b) Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr\/BCrp\/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 7:145\u2013152","journal-title":"Clin Cancer Res"},{"key":"9_CR217_9","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/sj.bjc.6601370","volume":"89","author":"RW Robey","year":"2003","unstructured":"Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M, Poruchynsky MS, Bates SE (2003) Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 89:1971\u20131978","journal-title":"Br J Cancer"},{"key":"9_CR218_9","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/0008-5472.CAN-03-3298","volume":"64","author":"RW Robey","year":"2004","unstructured":"Robey RW, Steadman K, Polgar O, Morisaki K, Blayney M, Mistry P, Bates SE (2004) Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res 64:1242\u20131246","journal-title":"Cancer Res"},{"key":"9_CR219_9","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4161\/cbt.4.2.1440","volume":"4","author":"RW Robey","year":"2005","unstructured":"Robey RW, Steadman K, Polgar O, Bates SE (2005) ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy. Cancer Biol Ther 4:187\u2013194","journal-title":"Cancer Biol Ther"},{"key":"9_CR220_9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00280-008-0908-2","volume":"64","author":"RW Robey","year":"2009","unstructured":"Robey RW, Obrzut T, Shukla S, Polgar O, Macalou S, Bahr JC, Di Pietro A, Ambudkar SV, Bates SE (2009) Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells. Cancer Chemother Pharmacol 64:575\u2013583","journal-title":"Cancer Chemother Pharmacol"},{"key":"9_CR221_9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/978-1-60761-416-6_12","volume":"596","author":"DD Ross","year":"2010","unstructured":"Ross DD, Nakanishi T (2010) Impact of breast cancer resistance protein on cancer treatment outcomes. Methods Mol Biol 596:251\u2013290","journal-title":"Methods Mol Biol"},{"key":"9_CR222_9","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1200\/JCO.2007.13.1128","volume":"26","author":"CM Rudin","year":"2008","unstructured":"Rudin CM, Liu W, Desai A, Karrison T, Jiang X, Janisch L, Das S, Ramirez J, Poonkuzhali B, Schuetz E, Fackenthal DL, Chen P, Armstrong DK, Brahmer JR, Fleming GF, Vokes EE, Carducci MA, Ratain MJ (2008) Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 26:1119\u20131127","journal-title":"J Clin Oncol"},{"issue":"1","key":"9_CR223_9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00280-009-1138-y","volume":"66","author":"K Sai","year":"2010","unstructured":"Sai K, Saito Y, Maekawa K, Kim SR, Kaniwa N, Nishimaki-Mogami T, Sawada JI, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Ohe Y, Yamada Y, Tamura T, Yoshida T, Matsumura Y, Ohtsu A, Saijo N, Minami H (2010) Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics\/pharmacodynamics in Japanese cancer patients. Cancer Chemother Pharmacol 66(1):95\u2013105","journal-title":"Cancer Chemother Pharmacol"},{"key":"9_CR224_9","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1155390","volume":"320","author":"R Sandberg","year":"2008","unstructured":"Sandberg R, Neilson JR, Sarma A, Sharp PA, Burge CB (2008) Proliferating cells express mRNAs with shortened 3\u2032 untranslated regions and fewer microRNA target sites. Science 320:1643\u20131647","journal-title":"Science"},{"key":"9_CR225_9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1365-2141.2002.03550.x","volume":"118","author":"A Sauerbrey","year":"2002","unstructured":"Sauerbrey A, Sell W, Steinbach D, Voigt A, Zintl F (2002) Expression of the BCRP gene (ABCG2\/MXR\/ABCP) in childhood acute lymphoblastic leukaemia. Br J Haematol 118:147\u2013150","journal-title":"Br J Haematol"},{"key":"9_CR226_9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood.V99.2.507","volume":"99","author":"CW Scharenberg","year":"2002","unstructured":"Scharenberg CW, Harkey MA, Torok-Storb B (2002) The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99:507\u2013512","journal-title":"Blood"},{"key":"9_CR227_9","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1749-6632.2000.tb07037.x","volume":"922","author":"JH Schellens","year":"2000","unstructured":"Schellens JH, Maliepaard M, Scheper RJ, Scheffer GL, Jonker JW, Smit JW, Beijnen JH, Schinkel AH (2000) Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann NY Acad Sci 922:188\u2013194","journal-title":"Ann NY Acad Sci"},{"key":"9_CR228_9","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/sj.bjp.0706974","volume":"150","author":"JA Schrickx","year":"2007","unstructured":"Schrickx JA, Fink-Gremmels J (2007) Danofloxacin-mesylate is a substrate for ATP-dependent efflux transporters. Br J Pharmacol 150:463\u2013469","journal-title":"Br J Pharmacol"},{"key":"9_CR229_9","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1158\/1535-7163.MCT-06-0339","volume":"5","author":"JA Seamon","year":"2006","unstructured":"Seamon JA, Rugg CA, Emanuel S, Calcagno AM, Ambudkar SV, Middleton SA, Butler J, Borowski V, Greenberger LM (2006) Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase\/Aurora kinase inhibitor. Mol Cancer Ther 5:2459\u20132467","journal-title":"Mol Cancer Ther"},{"key":"9_CR230_9","first-page":"729","volume":"11","author":"GM Seigel","year":"2005","unstructured":"Seigel GM, Campbell LM, Narayan M, Gonzalez-Fernandez F (2005) Cancer stem cell characteristics in retinoblastoma. Mol Vis 11:729\u2013737","journal-title":"Mol Vis"},{"key":"9_CR231_9","doi-asserted-by":"crossref","first-page":"8414","DOI":"10.1158\/0008-5472.CAN-04-4547","volume":"65","author":"A Shafran","year":"2005","unstructured":"Shafran A, Ifergan I, Bram E, Jansen G, Kathmann I, Peters GJ, Robey RW, Bates SE, Assaraf YG (2005) ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates. Cancer Res 65:8414\u20138422","journal-title":"Cancer Res"},{"key":"9_CR232_9","doi-asserted-by":"crossref","first-page":"5885","DOI":"10.1158\/0008-5472.CAN-09-0700","volume":"69","author":"J Shen","year":"2009","unstructured":"Shen J, Carcaboso AM, Hubbard KE, Tagen M, Wynn HG, Panetta JC, Waters CM, Elmeliegy MA, Stewart CF (2009) Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid. Cancer Res 69:5885\u20135892","journal-title":"Cancer Res"},{"key":"9_CR233_9","doi-asserted-by":"crossref","first-page":"11012","DOI":"10.1158\/0008-5472.CAN-07-2686","volume":"67","author":"Z Shi","year":"2007","unstructured":"Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T, Ashby CR Jr, Fu LW, Ambudkar SV, Chen ZS (2007) Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 67:11012\u201311020","journal-title":"Cancer Res"},{"key":"9_CR234_9","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00432-008-0407-1","volume":"134","author":"GM Shi","year":"2008","unstructured":"Shi GM, Xu Y, Fan J, Zhou J, Yang XR, Qiu SJ, Liao Y, Wu WZ, Ji Y, Ke AW, Ding ZB, He YZ, Wu B, Yang GH, Qin WZ, Zhang W, Zhu J, Min ZH, Wu ZQ (2008) Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J Cancer Res Clin Oncol 134:1155\u20131163","journal-title":"J Cancer Res Clin Oncol"},{"key":"9_CR235_9","first-page":"483","volume":"21","author":"Z Shi","year":"2009","unstructured":"Shi Z, Parmar S, Peng XX, Shen T, Robey RW, Bates SE, Fu LW, Shao Y, Chen YM, Zang F, Chen ZS (2009a) The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance. Oncol Rep 21:483\u2013489","journal-title":"Oncol Rep"},{"key":"9_CR236_9","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.bcp.2008.11.007","volume":"77","author":"Z Shi","year":"2009","unstructured":"Shi Z, Tiwari AK, Shukla S, Robey RW, Kim IW, Parmar S, Bates SE, Si QS, Goldblatt CS, Abraham I, Fu LW, Ambudkar SV, Chen ZS (2009b) Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol 77:781\u2013793","journal-title":"Biochem Pharmacol"},{"key":"9_CR237_9","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/ijc.11528","volume":"108","author":"K Shiozawa","year":"2004","unstructured":"Shiozawa K, Oka M, Soda H, Yoshikawa M, Ikegami Y, Tsurutani J, Nakatomi K, Nakamura Y, Doi S, Kitazaki T, Mizuta Y, Murase K, Yoshida H, Ross DD, Kohno S (2004) Reversal of breast cancer resistance protein (BCRP\/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. Int J Cancer 108:146\u2013151","journal-title":"Int J Cancer"},{"key":"9_CR238_9","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00277-008-0439-2","volume":"87","author":"TV Shman","year":"2008","unstructured":"Shman TV, Fedasenka UU, Savitski VP, Aleinikova OV (2008) CD34+ leukemic subpopulation predominantly displays lower spontaneous apoptosis and has higher expression levels of Bcl-2 and MDR1 genes than CD34- cells in childhood AML. Ann Hematol 87:353\u2013360","journal-title":"Ann Hematol"},{"key":"9_CR239_9","doi-asserted-by":"crossref","first-page":"8940","DOI":"10.1021\/bi060552f","volume":"45","author":"S Shukla","year":"2006","unstructured":"Shukla S, Robey RW, Bates SE, Ambudkar SV (2006) The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. Biochemistry 45:8940\u20138951","journal-title":"Biochemistry"},{"key":"9_CR240_9","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1158\/1535-7163.MCT-07-0564","volume":"6","author":"S Shukla","year":"2007","unstructured":"Shukla S, Wu CP, Nandigama K, Ambudkar SV (2007) The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance linked ATP binding cassette drug transporter ABCG2. Mol Cancer Ther 6:3279\u20133286","journal-title":"Mol Cancer Ther"},{"key":"9_CR241_9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1124\/dmd.108.024612","volume":"37","author":"S Shukla","year":"2009","unstructured":"Shukla S, Robey RW, Bates SE, Ambudkar SV (2009) Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 37:359\u2013365","journal-title":"Drug Metab Dispos"},{"key":"9_CR242_9","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ejps.2008.07.008","volume":"35","author":"HM Sim","year":"2008","unstructured":"Sim HM, Lee CY, Ee PL, Go ML (2008) Dimethoxyaurones: potent inhibitors of ABCG2 (breast cancer resistance protein). Eur J Pharm Sci 35:293\u2013306","journal-title":"Eur J Pharm Sci"},{"key":"9_CR243_9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clpt.2004.03.003","volume":"76","author":"A Sparreboom","year":"2004","unstructured":"Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe P, Twelves C, Verweij J, McLeod HL (2004) Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther 76:38\u201344","journal-title":"Clin Pharmacol Ther"},{"key":"9_CR244_9","doi-asserted-by":"crossref","first-page":"650","DOI":"10.4161\/cbt.4.6.1731","volume":"4","author":"A Sparreboom","year":"2005","unstructured":"Sparreboom A, Loos WJ, Burger H, Sissung TM, Verweij J, Figg WD, Nooter K, Gelderblom H (2005) Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol Ther 4:650\u2013658","journal-title":"Cancer Biol Ther"},{"key":"9_CR245_9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/sj.leu.2403168","volume":"18","author":"RW Stam","year":"2004","unstructured":"Stam RW, van den Heuvel-Eibrink MM, den Boer ML, Ebus ME, Janka-Schaub GE, Allen JD, Pieters R (2004) Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein. Leukemia 18:78\u201383","journal-title":"Leukemia"},{"key":"9_CR246_9","doi-asserted-by":"crossref","first-page":"e7729","DOI":"10.1371\/journal.pone.0007729","volume":"4","author":"K Stark","year":"2009","unstructured":"Stark K, Reinhard W, Grassl M, Erdmann J, Schunkert H, Illig T, Hengstenberg C (2009) Common polymorphisms influencing serum uric acid levels contribute to susceptibility to gout, but not to coronary artery disease. PLoS ONE 4:e7729","journal-title":"PLoS ONE"},{"key":"9_CR247_9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1124\/jpet.106.105023","volume":"319","author":"F Staud","year":"2006","unstructured":"Staud F, Vackova Z, Pospechova K, Pavek P, Ceckova M, Libra A, Cygalova L, Nachtigal P, Fendrich Z (2006) Expression and transport activity of breast cancer resistance protein (Bcrp\/Abcg2) in dually perfused rat placenta and HRP-1 cell line. J Pharmacol Exp Ther 319:53\u201362","journal-title":"J Pharmacol Exp Ther"},{"key":"9_CR248_9","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/sj.leu.2402541","volume":"16","author":"D Steinbach","year":"2002","unstructured":"Steinbach D, Sell W, Voigt A, Hermann J, Zintl F, Sauerbrey A (2002) BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 16:1443\u20131447","journal-title":"Leukemia"},{"key":"9_CR249_9","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1158\/0008-5472.CAN-04-0096","volume":"64","author":"CF Stewart","year":"2004","unstructured":"Stewart CF, Leggas M, Schuetz JD, Panetta JC, Cheshire PJ, Peterson J, Daw N, Jenkins JJ III, Gilbertson R, Germain GS, Harwood FC, Houghton PJ (2004) Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res 64:7491\u20137499","journal-title":"Cancer Res"},{"key":"9_CR250_9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1349-7006.2005.00081.x","volume":"96","author":"Y Sugimoto","year":"2005","unstructured":"Sugimoto Y, Tsukahara S, Ishikawa E, Mitsuhashi J (2005) Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics\/pharmacodynamics. Cancer Sci 96:457\u2013465","journal-title":"Cancer Sci"},{"key":"9_CR251_9","first-page":"2967","volume":"28","author":"P Surowiak","year":"2008","unstructured":"Surowiak P, Pawelczyk K, Maciejczyk A, Pudelko M, Kolodziej J, Zabel M, Murawa D, Drag M, Gansukh T, Dietel M, Lage H (2008) Positive correlation between cyclooxygenase 2 and the expression of ABC transporters in non-small cell lung cancer. Anticancer Res 28:2967\u20132974","journal-title":"Anticancer Res"},{"key":"9_CR252_9","doi-asserted-by":"crossref","first-page":"22644","DOI":"10.1074\/jbc.M212399200","volume":"278","author":"M Suzuki","year":"2003","unstructured":"Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y (2003) ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem 278:22644\u201322649","journal-title":"J Biol Chem"},{"key":"9_CR253_9","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ejca.2005.09.017","volume":"42","author":"K Swerts","year":"2006","unstructured":"Swerts K, De Moerloose B, Dhooge C, Laureys G, Benoit Y, Philippe J (2006) Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemia. Eur J Cancer 42:295\u2013309","journal-title":"Eur J Cancer"},{"issue":"4","key":"9_CR254_9","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.bmcl.2010.01.016","volume":"20","author":"K Takada","year":"2010","unstructured":"Takada K, Imamura N, Gustafson KR, Henrich CJ (2010) Synthesis and structure-activity relationship of botryllamides that block the ABCG2 multidrug transporter. Bioorg Med Chem Lett 20(4):1330\u20131333","journal-title":"Bioorg Med Chem Lett"},{"key":"9_CR255_9","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.canlet.2008.12.033","volume":"278","author":"K Takara","year":"2009","unstructured":"Takara K, Kitada N, Yoshikawa E, Yamamoto K, Horibe S, Sakaeda T, Nishiguchi K, Ohnishi N, Yokoyama T (2009) Molecular changes to HeLa cells on continuous exposure to SN-38, an active metabolite of irinotecan hydrochloride. Cancer Lett 278:88\u201396","journal-title":"Cancer Lett"},{"key":"9_CR256_9","first-page":"983","volume":"17","author":"N Takigawa","year":"2007","unstructured":"Takigawa N, Takeyama M, Kozuki T, Shibayama T, Hisamoto A, Kiura K, Tada A, Hotta K, Umemura S, Ohashi K, Fujiwara Y, Takata S, Ichihara E, Osawa M, Tabata M, Tanimoto M, Takahashi K (2007) Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells. Oncol Rep 17:983\u2013987","journal-title":"Oncol Rep"},{"key":"9_CR257_9","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/mol.106.023556","volume":"70","author":"A Tamura","year":"2006","unstructured":"Tamura A, Watanabe M, Saito H, Nakagawa H, Kamachi T, Okura I, Ishikawa T (2006) Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport. Mol Pharmacol 70:287\u2013296","journal-title":"Mol Pharmacol"},{"key":"9_CR258_9","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1349-7006.2006.00371.x","volume":"98","author":"A Tamura","year":"2007","unstructured":"Tamura A, Wakabayashi K, Onishi Y, Takeda M, Ikegami Y, Sawada S, Tsuji M, Matsuda Y, Ishikawa T (2007) Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2. Cancer Sci 98:231\u2013239","journal-title":"Cancer Sci"},{"key":"9_CR259_9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1517\/17425255.4.3.255","volume":"4","author":"A Tamura","year":"2008","unstructured":"Tamura A, An R, Hagiya Y, Hoshijima K, Yoshida T, Mikuriya K, Ishikawa T (2008) Drug-induced phototoxicity evoked by inhibition of human ABC transporter ABCG2: development of in vitro high-speed screening systems. Expert Opin Drug Metab Toxicol 4:255\u2013272","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"9_CR260_9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bbrc.2004.11.012","volume":"326","author":"Y Tanaka","year":"2005","unstructured":"Tanaka Y, Slitt AL, Leazer TM, Maher JM, Klaassen CD (2005) Tissue distribution and hormonal regulation of the breast cancer resistance protein (Bcrp\/Abcg2) in rats and mice. Biochem Biophys Res Commun 326:181\u2013187","journal-title":"Biochem Biophys Res Commun"},{"key":"9_CR261_9","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1634\/stemcells.2006-0567","volume":"25","author":"WG Telford","year":"2007","unstructured":"Telford WG, Bradford J, Godfrey W, Robey RW, Bates SE (2007) Side population analysis using a violet-excited cell-permeable DNA binding dye. Stem Cells 25:1029\u20131036","journal-title":"Stem Cells"},{"key":"9_CR262_9","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1016\/j.ejca.2009.05.007","volume":"45","author":"F Thomas","year":"2009","unstructured":"Thomas F, Rochaix P, White-Koning M, Hennebelle I, Sarini J, Benlyazid A, Malard L, Lefebvre JL, Chatelut E, Delord JP (2009) Population pharmacokinetics of erlotinib and its pharmacokinetic\/pharmacodynamic relationships in head and neck squamous cell carcinoma. Eur J Cancer 45:2316\u20132323","journal-title":"Eur J Cancer"},{"key":"9_CR263_9","doi-asserted-by":"crossref","first-page":"e3469","DOI":"10.1371\/journal.pone.0003469","volume":"3","author":"V Tirino","year":"2008","unstructured":"Tirino V, Desiderio V, d'Aquino R, De Francesco F, Pirozzi G, Graziano A, Galderisi U, Cavaliere C, De Rosa A, Papaccio G, Giordano A (2008) Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS ONE 3:e3469","journal-title":"PLoS ONE"},{"key":"9_CR264_9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bcp.2009.04.002","volume":"78","author":"AK Tiwari","year":"2009","unstructured":"Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS (2009) Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1\/Pgp and ABCG2\/BCRP\/MXR transporters. Biochem Pharmacol 78:153\u2013161","journal-title":"Biochem Pharmacol"},{"key":"9_CR265_9","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1128\/MCB.00331-08","volume":"28","author":"KK To","year":"2008","unstructured":"To KK, Zhan Z, Litman T, Bates SE (2008) Regulation of ABCG2 expression at the 3\u2032 untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. Mol Cell Biol 28:5147\u20135161","journal-title":"Mol Cell Biol"},{"key":"9_CR266_9","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1158\/1535-7163.MCT-09-0292","volume":"8","author":"KK To","year":"2009","unstructured":"To KK, Robey RW, Knutsen T, Zhan Z, Ried T, Bates SE (2009) Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2. Mol Cancer Ther 8:2959\u20132968","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"9_CR267_9","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/clpt.2009.232","volume":"87","author":"B Tomlinson","year":"2010","unstructured":"Tomlinson B, Hu M, Lee VW, Lui SS, Chu TT, Poon EW, Ko GT, Baum L, Tam LS, Li EK (2010) ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther 87(5):558\u2013562","journal-title":"Clin Pharmacol Ther"},{"key":"9_CR268_9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000106787","volume":"71","author":"S Tsunoda","year":"2006","unstructured":"Tsunoda S, Okumura T, Ito T, Kondo K, Ortiz C, Tanaka E, Watanabe G, Itami A, Sakai Y, Shimada Y (2006) ABCG2 expression is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma. Oncology 71:251\u2013258","journal-title":"Oncology"},{"key":"9_CR269_9","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1182\/blood-2005-10-009084","volume":"108","author":"JG Turner","year":"2006","unstructured":"Turner JG, Gump JL, Zhang C, Cook JM, Marchion D, Hazlehurst L, Munster P, Schell MJ, Dalton WS, Sullivan DM (2006) ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood 108:3881\u20133889","journal-title":"Blood"},{"key":"9_CR270_9","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.bbrc.2006.01.037","volume":"341","author":"A Uezumi","year":"2006","unstructured":"Uezumi A, Ojima K, Fukada S, Ikemoto M, Masuda S, Miyagoe-Suzuki Y, Takeda S (2006) Functional heterogeneity of side population cells in skeletal muscle. Biochem Biophys Res Commun 341:864\u2013873","journal-title":"Biochem Biophys Res Commun"},{"key":"9_CR271_9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.leukres.2004.06.004","volume":"29","author":"B Uggla","year":"2005","unstructured":"Uggla B, Stahl E, Wagsater D, Paul C, Karlsson MG, Sirsjo A, Tidefelt U (2005) BCRP mRNA expression v. clinical outcome in 40 adult AML patients. Leuk Res 29:141\u2013146","journal-title":"Leuk Res"},{"key":"9_CR272_9","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/FPC.0b013e3282f974dc","volume":"18","author":"BL Urquhart","year":"2008","unstructured":"Urquhart BL, Ware JA, Tirona RG, Ho RH, Leake BF, Schwarz UI, Zaher H, Palandra J, Gregor JC, Dresser GK, Kim RB (2008) Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Pharmacogenet Genomics 18:439\u2013448","journal-title":"Pharmacogenet Genomics"},{"key":"9_CR273_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-007-9382-7","volume":"85","author":"ET Valera","year":"2007","unstructured":"Valera ET, Lucio-Eterovic AK, Neder L, Scrideli CA, Machado HR, Carlotti-Junior CG, Queiroz RG, Motta FJ, Tone LG (2007) Quantitative PCR analysis of the expression profile of genes related to multiple drug resistance in tumors of the central nervous system. J Neurooncol 85:1\u201310","journal-title":"J Neurooncol"},{"key":"9_CR274_9","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/sj.leu.2402496","volume":"16","author":"MM van den Heuvel-Eibrink","year":"2002","unstructured":"van den Heuvel-Eibrink MM, Wiemer EA, Prins A, Meijerink JP, Vossebeld PJ, van der Holt B, Pieters R, Sonneveld P (2002) Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). Leukemia 16:833\u2013839","journal-title":"Leukemia"},{"key":"9_CR275_9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00277-007-0269-7","volume":"86","author":"MM van den Heuvel-Eibrink","year":"2007","unstructured":"van den Heuvel-Eibrink MM, van der Holt B, Burnett AK, Knauf WU, Fey MF, Verhoef GE, Vellenga E, Ossenkoppele GJ, Lowenberg B, Sonneveld P (2007) CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann Hematol 86:329\u2013337","journal-title":"Ann Hematol"},{"key":"9_CR276_9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/ard.2003.006494","volume":"63","author":"J van der Heijden","year":"2004","unstructured":"van der Heijden J, de Jong MC, Dijkmans BA, Lems WF, Oerlemans R, Kathmann I, Scheffer GL, Scheper RJ, Assaraf YG, Jansen G (2004) Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs. Ann Rheum Dis 63:131\u2013137","journal-title":"Ann Rheum Dis"},{"key":"9_CR277_9","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1182\/blood.V99.10.3763","volume":"99","author":"DM van der Kolk","year":"2002","unstructured":"van der Kolk DM, Vellenga E, Scheffer GL, Muller M, Bates SE, Scheper RJ, de Vries EG (2002) Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood 99:3763\u20133770","journal-title":"Blood"},{"key":"9_CR278_9","first-page":"134","volume":"88","author":"MA van der Pol","year":"2003","unstructured":"van der Pol MA, Broxterman HJ, Pater JM, Feller N, van der Mass M, Weijers GW, Scheffer GL, Allen JD, Scheper RJ, van Loevezijn A, Ossenkoppele GJ, Schuurhuis GJ (2003) Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia. Haematologica 88:134\u2013147","journal-title":"Haematologica"},{"key":"9_CR279_9","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1200\/JCO.2008.21.7679","volume":"27","author":"NP van Erp","year":"2009","unstructured":"van Erp NP, Eechoute K, van der Veldt AA, Haanen JB, Reyners AK, Mathijssen RH, Boven E, van der Straaten T, Baak-Pablo RF, Wessels JA, Guchelaar HJ, Gelderblom H (2009) Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 27:4406\u20134412","journal-title":"J Clin Oncol"},{"key":"9_CR280_9","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/sj.bjc.6600508","volume":"87","author":"AH Van Hattum","year":"2002","unstructured":"Van Hattum AH, Hoogsteen IJ, Schluper HM, Maliepaard M, Scheffer GL, Scheper RJ, Kohlhagen G, Pommier Y, Pinedo HM, Boven E (2002a) Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity. Br J Cancer 87:665\u2013672","journal-title":"Br J Cancer"},{"key":"9_CR281_9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ijc.10434","volume":"100","author":"AH Van Hattum","year":"2002","unstructured":"Van Hattum AH, Schluper HM, Hausheer FH, Pinedo HM, Boven E (2002b) Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance. Int J Cancer 100:22\u201329","journal-title":"Int J Cancer"},{"key":"9_CR282_9","first-page":"6447","volume":"63","author":"AE van Herwaarden","year":"2003","unstructured":"van Herwaarden AE, Jonker JW, Wagenaar E, Brinkhuis RF, Schellens JH, Beijnen JH, Schinkel AH (2003) The breast cancer resistance protein (Bcrp1\/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine. Cancer Res 63:6447\u20136452","journal-title":"Cancer Res"},{"key":"9_CR283_9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/carcin\/bgi176","volume":"27","author":"AE van Herwaarden","year":"2006","unstructured":"van Herwaarden AE, Wagenaar E, Karnekamp B, Merino G, Jonker JW, Schinkel AH (2006) Breast cancer resistance protein (Bcrp1\/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. Carcinogenesis 27:123\u2013130","journal-title":"Carcinogenesis"},{"key":"9_CR284_9","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1128\/MCB.01621-06","volume":"27","author":"AE van Herwaarden","year":"2007","unstructured":"van Herwaarden AE, Wagenaar E, Merino G, Jonker JW, Rosing H, Beijnen JH, Schinkel AH (2007) Multidrug transporter ABCG2\/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk. Mol Cell Biol 27:1247\u20131253","journal-title":"Mol Cell Biol"},{"key":"9_CR285_9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0960-894X(00)00588-6","volume":"11","author":"A van Loevezijn","year":"2001","unstructured":"van Loevezijn A, Allen JD, Schinkel AH, Koomen GJ (2001) Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines. Bioorg Med Chem Lett 11:29\u201332","journal-title":"Bioorg Med Chem Lett"},{"key":"9_CR286_9","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/j.1872-034X.2008.00381.x","volume":"38","author":"BS Vander","year":"2008","unstructured":"Vander BS, van Pelt J, van Malenstein H, Cassiman D, Renard M, Verslype C, Libbrecht L, Roskams TA (2008) Up-regulation of breast cancer resistance protein expression in hepatoblastoma following chemotherapy: A study in patients and in vitro. Hepatol Res 38:1112\u20131121","journal-title":"Hepatol Res"},{"key":"9_CR287_9","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1124\/dmd.105.003657","volume":"33","author":"RR Vethanayagam","year":"2005","unstructured":"Vethanayagam RR, Wang H, Gupta A, Zhang Y, Lewis F, Unadkat JD, Mao Q (2005) Functional analysis of the human variants of breast cancer resistance protein: I206L, N590Y, and D620N. Drug Metab Dispos 33:697\u2013705","journal-title":"Drug Metab Dispos"},{"key":"9_CR288_9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.addr.2008.08.007","volume":"61","author":"ML Vlaming","year":"2009","unstructured":"Vlaming ML, Lagas JS, Schinkel AH (2009a) Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. Adv Drug Deliv Rev 61:14\u201325","journal-title":"Adv Drug Deliv Rev"},{"key":"9_CR289_9","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1158\/1078-0432.CCR-08-2940","volume":"15","author":"ML Vlaming","year":"2009","unstructured":"Vlaming ML, Pala Z, van Esch A, Wagenaar E, de Waart DR, van de Wetering K, van der Kruijssen CM, Oude Elferink RP, van Tellingen O, Schinkel AH (2009b) Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo. Clin Cancer Res 15:3084\u20133093","journal-title":"Clin Cancer Res"},{"key":"9_CR290_9","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1158\/1535-7163.MCT-09-0668","volume":"8","author":"ML Vlaming","year":"2009","unstructured":"Vlaming ML, van Esch A, Pala Z, Wagenaar E, van de Wetering K, van Tellingen O, Schinkel AH (2009c) Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Mol Cancer Ther 8:3350\u20133359","journal-title":"Mol Cancer Ther"},{"key":"9_CR291_9","first-page":"5538","volume":"63","author":"EL Volk","year":"2003","unstructured":"Volk EL, Schneider E (2003) Wild-type breast cancer resistance protein (BCRP\/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 63:5538\u20135543","journal-title":"Cancer Res"},{"key":"9_CR292_9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/095632020501600401","volume":"16","author":"X Wang","year":"2005","unstructured":"Wang X, Baba M (2005) The role of breast cancer resistance protein (BCRP\/ABCG2) in cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Antivir Chem Chemother 16:213\u2013216","journal-title":"Antivir Chem Chemother"},{"key":"9_CR293_9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1124\/dmd.106.011684","volume":"35","author":"X Wang","year":"2007","unstructured":"Wang X, Morris ME (2007) Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2. Drug Metab Dispos 35:268\u2013274","journal-title":"Drug Metab Dispos"},{"key":"9_CR294_9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1124\/mol.63.1.65","volume":"63","author":"X Wang","year":"2003","unstructured":"Wang X, Furukawa T, Nitanda T, Okamoto M, Sugimoto Y, Akiyama S, Baba M (2003) Breast cancer resistance protein (BCRP\/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol 63:65\u201372","journal-title":"Mol Pharmacol"},{"key":"9_CR295_9","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4149\/neo_2009_05_371","volume":"56","author":"YH Wang","year":"2009","unstructured":"Wang YH, Li F, Luo B, Wang XH, Sun HC, Liu S, Cui YQ, Xu XX (2009) A side population of cells from a human pancreatic carcinoma cell line harbors cancer stem cell characteristics. Neoplasma 56:371\u2013378","journal-title":"Neoplasma"},{"key":"9_CR296_9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00439-009-0760-4","volume":"127","author":"B Wang","year":"2010","unstructured":"Wang B, Miao Z, Liu S, Wang J, Zhou S, Han L, Meng D, Wang Y, Li C, Ma X (2010) Genetic analysis of ABCG2 gene C421A polymorphism with gout disease in Chinese Han male population. Hum Genet 127:245\u2013246","journal-title":"Hum Genet"},{"key":"9_CR297_9","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/jid.2008.16","volume":"128","author":"RB Warren","year":"2008","unstructured":"Warren RB, Smith RL, Campalani E, Eyre S, Smith CH, Barker JN, Worthington J, Griffiths CE (2008) Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol 128:1925\u20131929","journal-title":"J Invest Dermatol"},{"key":"9_CR298_9","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.phrs.2009.02.007","volume":"59","author":"MS Warren","year":"2009","unstructured":"Warren MS, Zerangue N, Woodford K, Roberts LM, Tate EH, Feng B, Li C, Feuerstein TJ, Gibbs J, Smith B, de Morais SM, Dower WJ, Koller KJ (2009) Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human. Pharmacol Res 59:404\u2013413","journal-title":"Pharmacol Res"},{"key":"9_CR299_9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/jac\/dkl474","volume":"59","author":"J Weiss","year":"2007","unstructured":"Weiss J, Rose J, Storch CH, Ketabi-Kiyanvash N, Sauer A, Haefeli WE, Efferth T (2007) Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 59:238\u2013245","journal-title":"J Antimicrob Chemother"},{"key":"9_CR300_9","doi-asserted-by":"crossref","first-page":"10338","DOI":"10.1073\/pnas.0901249106","volume":"106","author":"OM Woodward","year":"2009","unstructured":"Woodward OM, Kottgen A, Coresh J, Boerwinkle E, Guggino WB, Kottgen M (2009) Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A 106:10338\u201310342","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9_CR301_9","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1517\/17425255.1.4.595","volume":"1","author":"CQ Xia","year":"2005","unstructured":"Xia CQ, Yang JJ, Gan LS (2005) Breast cancer resistance protein in pharmacokinetics and drug\u2013drug interactions. Expert Opin Drug Metab Toxicol 1:595\u2013611","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"9_CR302_9","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1124\/dmd.106.011866","volume":"35","author":"CQ Xia","year":"2007","unstructured":"Xia CQ, Liu N, Miwa GT, Gan LS (2007) Interactions of cyclosporin a with breast cancer resistance protein. Drug Metab Dispos 35:576\u2013582","journal-title":"Drug Metab Dispos"},{"key":"9_CR303_9","first-page":"273","volume":"35","author":"T Yajima","year":"2009","unstructured":"Yajima T, Ochiai H, Uchiyama T, Takano N, Shibahara T, Azuma T (2009) Resistance to cytotoxic chemotherapy-induced apoptosis in side population cells of human oral squamous cell carcinoma cell line Ho-1-N-1. Int J Oncol 35:273\u2013280","journal-title":"Int J Oncol"},{"key":"9_CR304_9","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1124\/dmd.106.014217","volume":"35","author":"T Yamagata","year":"2007","unstructured":"Yamagata T, Kusuhara H, Morishita M, Takayama K, Benameur H, Sugiyama Y (2007) Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients. Drug Metab Dispos 35:1142\u20131148","journal-title":"Drug Metab Dispos"},{"key":"9_CR305_9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/sj.clpt.6100459","volume":"84","author":"Y Yamasaki","year":"2008","unstructured":"Yamasaki Y, Ieiri I, Kusuhara H, Sasaki T, Kimura M, Tabuchi H, Ando Y, Irie S, Ware J, Nakai Y, Higuchi S, Sugiyama Y (2008) Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. Clin Pharmacol Ther 84:95\u2013103","journal-title":"Clin Pharmacol Ther"},{"key":"9_CR306_9","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1158\/1535-7163.1119.3.9","volume":"3","author":"K Yanase","year":"2004","unstructured":"Yanase K, Tsukahara S, Asada S, Ishikawa E, Imai Y, Sugimoto Y (2004) Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol Cancer Ther 3:1119\u20131125","journal-title":"Mol Cancer Ther"},{"key":"9_CR307_9","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0006-2952(00)00396-8","volume":"60","author":"CH Yang","year":"2000","unstructured":"Yang CH, Schneider E, Kuo ML, Volk EL, Rocchi E, Chen YC (2000) BCRP\/MXR\/ABCP expression in topotecan-resistant human breast carcinoma cells. Biochem Pharmacol 60:831\u2013837","journal-title":"Biochem Pharmacol"},{"key":"9_CR308_9","first-page":"2519","volume":"23","author":"CH Yang","year":"2003","unstructured":"Yang CH, Chen YC, Kuo ML (2003) Novobiocin sensitizes BCRP\/MXR\/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone. Anticancer Res 23:2519\u20132523","journal-title":"Anticancer Res"},{"key":"9_CR309_9","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1349-7006.2008.00936.x","volume":"99","author":"H Yano","year":"2008","unstructured":"Yano H, Kayukawa S, Iida S, Nakagawa C, Oguri T, Sanda T, Ding J, Mori F, Ito A, Ri M, Inagaki A, Kusumoto S, Ishida T, Komatsu H, Inagaki H, Suzuki A, Ueda R (2008) Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma. Cancer Sci 99:2309\u20132314","journal-title":"Cancer Sci"},{"key":"9_CR310_9","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1271\/bbb.69.1871","volume":"69","author":"S Yasuda","year":"2005","unstructured":"Yasuda S, Itagaki S, Hirano T, Iseki K (2005) Expression level of ABCG2 in the placenta decreases from the mid stage to the end of gestation. Biosci Biotechnol Biochem 69:1871\u20131876","journal-title":"Biosci Biotechnol Biochem"},{"key":"9_CR311_9","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1139\/y06-078","volume":"84","author":"D Yeboah","year":"2006","unstructured":"Yeboah D, Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W (2006) Expression of breast cancer resistance protein (BCRP\/ABCG2) in human placenta throughout gestation and at term before and after labor. Can J Physiol Pharmacol 84:1251\u20131258","journal-title":"Can J Physiol Pharmacol"},{"key":"9_CR312_9","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1158\/1078-0432.CCR-0937-3","volume":"10","author":"K Yoh","year":"2004","unstructured":"Yoh K, Ishii G, Yokose T, Minegishi Y, Tsuta K, Goto K, Nishiwaki Y, Kodama T, Suga M, Ochiai A (2004) Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res 10:1691\u20131697","journal-title":"Clin Cancer Res"},{"key":"9_CR313_9","first-page":"25","volume":"4","author":"M Yoshikawa","year":"2004","unstructured":"Yoshikawa M, Ikegami Y, Sano K, Yoshida H, Mitomo H, Sawada S, Ishikawa T (2004) Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid. J Exp Ther Oncol 4:25\u201335","journal-title":"J Exp Ther Oncol"},{"key":"9_CR314_9","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1007\/s11095-007-9235-2","volume":"24","author":"S Yoshioka","year":"2007","unstructured":"Yoshioka S, Katayama K, Okawa C, Takahashi S, Tsukahara S, Mitsuhashi J, Sugimoto Y (2007) The identification of two germ-line mutations in the human breast cancer resistance protein gene that result in the expression of a low\/non-functional protein. Pharm Res 24:1108\u20131117","journal-title":"Pharm Res"},{"key":"9_CR315_9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1021\/mp050113v","volume":"3","author":"H Zaher","year":"2006","unstructured":"Zaher H, Khan AA, Palandra J, Brayman TG, Yu L, Ware JA (2006) Breast cancer resistance protein (Bcrp\/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol Pharm 3:55\u201361","journal-title":"Mol Pharm"},{"key":"9_CR316_9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00008571-200301000-00004","volume":"13","author":"CP Zamber","year":"2003","unstructured":"Zamber CP, Lamba JK, Yasuda K, Farnum J, Thummel K, Schuetz JD, Schuetz EG (2003) Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 13:19\u201328","journal-title":"Pharmacogenetics"},{"key":"9_CR317_9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s10637-006-6335-5","volume":"24","author":"WC Zamboni","year":"2006","unstructured":"Zamboni WC, Ramanathan RK, McLeod HL, Mani S, Potter DM, Strychor S, Maruca LJ, King CR, Jung LL, Parise RA, Egorin MJ, Davis TA, Marsh S (2006) Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes. Invest New Drugs 24:393\u2013401","journal-title":"Invest New Drugs"},{"key":"9_CR318_9","first-page":"2085","volume":"17","author":"W Zhang","year":"2003","unstructured":"Zhang W, Mojsilovic-Petrovic J, Andrade MF, Zhang H, Ball M, Stanimirovic DB (2003) The expression and functional characterization of ABCG2 in brain endothelial cells and vessels. FASEB J 17:2085\u20132087","journal-title":"FASEB J"},{"key":"9_CR319_9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1124\/dmd.104.002501","volume":"33","author":"S Zhang","year":"2005","unstructured":"Zhang S, Wang X, Sagawa K, Morris ME (2005a) Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a\/1b (\u2212\/\u2212) mice. Drug Metab Dispos 33:341\u2013348","journal-title":"Drug Metab Dispos"},{"key":"9_CR320_9","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1007\/s11095-005-8384-4","volume":"22","author":"Y Zhang","year":"2005","unstructured":"Zhang Y, Gupta A, Wang H, Zhou L, Vethanayagam RR, Unadkat JD, Mao Q (2005b) BCRP transports dipyridamole and is inhibited by calcium channel blockers. Pharm Res 22:2023\u20132034","journal-title":"Pharm Res"},{"key":"9_CR321_9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cca.2006.05.010","volume":"373","author":"W Zhang","year":"2006","unstructured":"Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ, Wang A, Liu YL, Tan ZR, Fen J, Huang YF, Zhou HH (2006) Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta 373:99\u2013103","journal-title":"Clin Chim Acta"},{"key":"9_CR322_9","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1124\/dmd.107.018044","volume":"35","author":"Y Zhang","year":"2007","unstructured":"Zhang Y, Wang H, Unadkat JD, Mao Q (2007) Breast cancer resistance protein 1 limits fetal distribution of nitrofurantoin in the pregnant mouse. Drug Metab Dispos 35:2154\u20132158","journal-title":"Drug Metab Dispos"},{"key":"9_CR323_9","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1158\/0008-5472.CAN-08-0364","volume":"68","author":"S Zhang","year":"2008","unstructured":"Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP (2008) Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68:4311\u20134320","journal-title":"Cancer Res"},{"key":"9_CR324_9","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.canlet.2008.12.015","volume":"277","author":"P Zhang","year":"2009","unstructured":"Zhang P, Zhang Y, Mao L, Zhang Z, Chen W (2009) Side population in oral squamous cell carcinoma possesses tumor stem cell phenotypes. Cancer Lett 277:227\u2013234","journal-title":"Cancer Lett"},{"key":"9_CR325_9","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1124\/dmd.108.025064","volume":"37","author":"R Zhao","year":"2009","unstructured":"Zhao R, Raub TJ, Sawada GA, Kasper SC, Bacon JA, Bridges AS, Pollack GM (2009) Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efflux at the blood\u2013brain barrier. Drug Metab Dispos 37:1251\u20131258","journal-title":"Drug Metab Dispos"},{"key":"9_CR326_9","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm0901-1028","volume":"7","author":"S Zhou","year":"2001","unstructured":"Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP (2001) The ABC transporter Bcrp1\/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7:1028\u20131034","journal-title":"Nat Med"},{"key":"9_CR327_9","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.2144\/03356ss04","volume":"35","author":"S Zhou","year":"2003","unstructured":"Zhou S, Zong Y, Lu T, Sorrentino BP (2003) Hematopoietic cells from mice that are deficient in both Bcrp1\/Abcg2 and Mdr1a\/1b develop normally but are sensitized to mitoxantrone. Biotechniques 35:1248\u20131252","journal-title":"Biotechniques"},{"key":"9_CR328_9","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2125.2004.02330.x","volume":"59","author":"Q Zhou","year":"2005","unstructured":"Zhou Q, Sparreboom A, Tan EH, Cheung YB, Lee A, Poon D, Lee EJ, Chowbay B (2005a) Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br J Clin Pharmacol 59:415\u2013424","journal-title":"Br J Clin Pharmacol"},{"key":"9_CR329_9","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/blood-2004-04-1566","volume":"105","author":"S Zhou","year":"2005","unstructured":"Zhou S, Zong Y, Ney PA, Nair G, Stewart CF, Sorrentino BP (2005b) Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels. Blood 105:2571\u20132576","journal-title":"Blood"},{"key":"9_CR330_9","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1124\/dmd.104.003558","volume":"33","author":"XF Zhou","year":"2005","unstructured":"Zhou XF, Yang X, Wang Q, Coburn RA, Morris ME (2005c) Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies. Drug Metab Dispos 33:1220\u20131228","journal-title":"Drug Metab Dispos"},{"key":"9_CR331_9","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3748\/wjg.14.925","volume":"14","author":"J Zhou","year":"2008","unstructured":"Zhou J, Wang CY, Liu T, Wu B, Zhou F, Xiong JX, Wu HS, Tao J, Zhao G, Yang M, Gou SM (2008a) Persistence of side population cells with high drug efflux capacity in pancreatic cancer. World J Gastroenterol 14:925\u2013930","journal-title":"World J Gastroenterol"},{"key":"9_CR332_9","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1124\/mol.107.041616","volume":"73","author":"L Zhou","year":"2008","unstructured":"Zhou L, Naraharisetti SB, Wang H, Unadkat JD, Hebert MF, Mao Q (2008b) The breast cancer resistance protein (Bcrp1\/Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study. Mol Pharmacol 73:949\u2013959","journal-title":"Mol Pharmacol"},{"issue":"9","key":"9_CR333_9","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1002\/ijc.24868","volume":"126","author":"Z Zhu","year":"2010","unstructured":"Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J, Li J (2010) Cancer stem\/progenitor cells are highly enriched in CD133(+)CD44(+) population in hepatocellular carcinoma. Int J Cancer 126(9):2067\u20132078","journal-title":"Int J Cancer"},{"key":"9_CR334_9","doi-asserted-by":"crossref","first-page":"11305","DOI":"10.1158\/0008-5472.CAN-06-0929","volume":"66","author":"Y Zhuang","year":"2006","unstructured":"Zhuang Y, Fraga CH, Hubbard KE, Hagedorn N, Panetta JC, Waters CM, Stewart CF (2006) Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. Cancer Res 66:11305\u201311313","journal-title":"Cancer Res"},{"key":"9_CR335_9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000097800","volume":"74","author":"C Zimmermann","year":"2006","unstructured":"Zimmermann C, Hruz P, Gutmann H, Terracciano L, Beuers U, Lehmann F, Beglinger C, Drewe J (2006) Decreased expression of breast cancer resistance protein in the duodenum in patients with obstructive cholestasis. Digestion 74:101\u2013108","journal-title":"Digestion"}],"container-title":["Handbook of Experimental Pharmacology","Drug Transporters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-14541-4_9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T04:25:55Z","timestamp":1740716755000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-642-14541-4_9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,26]]},"ISBN":["9783642145407","9783642145414"],"references-count":335,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-14541-4_9","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,26]]},"assertion":[{"value":"26 October 2010","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}